

# 1 **Untargeted proteomics enables ultra-rapid variant prioritization in mitochondrial** 2 **and other rare diseases**

3  
4 Daniella H. Hock<sup>1,2,3,\*</sup>, Nikeisha J. Caruana<sup>1,4</sup>, Liana N. Semcesen<sup>1</sup>, Nicole J. Lake<sup>5</sup>, Luke  
5 E. Formosa<sup>6</sup>, Sumudu S. C. Amarasekera<sup>2</sup>, Tegan Stait<sup>2</sup>, Simone Tregoning<sup>2</sup>, Leah E.  
6 Frajman<sup>2</sup>, David R. L. Robinson<sup>1</sup>, Megan Ball<sup>2,10,12</sup>, Boris Reljic<sup>1,6</sup>, Bryony Ryder<sup>7</sup>, Mathew  
7 J. Wallis<sup>8,9</sup>, Anand Vasudevan<sup>10</sup>, Cara Beck<sup>3</sup>, Heidi Peters<sup>11,12</sup>, Joy Lee<sup>3,11</sup>, Natalie B.  
8 Tan<sup>2,3,12</sup>, Mary-Louise Freckmann<sup>13</sup>, MitoMDT Diagnostic Network for Genomics and  
9 Omics<sup>\*\*</sup>, Vasiliki Karlaftis<sup>2,12</sup>, Chantal Attard<sup>2,12</sup>, Paul Monagle<sup>2,12,14,15</sup>, Amanda  
10 Samarasinghe<sup>2</sup>, Rosie Brown<sup>2,3</sup>, Weimin Bi<sup>16,17</sup>, Monkol Lek<sup>5</sup>, Robert McFarland<sup>18,19</sup>,  
11 Robert W. Taylor<sup>18,19</sup>, Michael T. Ryan<sup>6</sup>, Zornitza Stark<sup>2,3,12</sup>, John Christodoulou<sup>2,3,12</sup>,  
12 Alison G. Compton<sup>2,3,12</sup>, David R. Thorburn<sup>2,3,12\*</sup>, David A. Stroud<sup>1,2,3\*</sup>

## 13 14 Affiliations

15 <sup>1</sup>Department of Biochemistry and Pharmacology, Bio21 Molecular Science and  
16 Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia

17 <sup>2</sup>Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia

18 <sup>3</sup>Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne,  
19 VIC, 3052, Australia

20 <sup>4</sup>Institute for Health and Sport (iHeS), Victoria University, Melbourne, VIC, 3011, Australia

21 <sup>5</sup>Department of Genetics, Yale School of Medicine, New Haven, CT 06510 USA

22 <sup>6</sup>Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery  
23 Institute, Monash University, 3800, Melbourne, Australia

24 <sup>7</sup>Paediatric and Adult National Metabolic Service, Te Toka Tumai, Te Whatu Ora Health  
25 New Zealand, Auckland, New Zealand

26 <sup>8</sup>Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS 7001,  
27 Australia

28 <sup>9</sup>School of Medicine and Menzies institute for Medical Research, University of Tasmania,  
29 Hobart, TAS 7001, Australia

30 <sup>10</sup>Royal Women's Hospital, Melbourne, VIC, 3052, Australia

31 <sup>11</sup>Department of Metabolic Medicine, Royal Children's Hospital, Melbourne, VIC 3052,  
32 Australia

33 <sup>12</sup>Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia

34 <sup>13</sup>Department of Clinical Genetics, The Canberra Hospital, Canberra, Australian Capital  
35 Territory, Australia

36 <sup>14</sup>Department of Haematology, Royal Children's Hospital, Parkville VIC, Australia

37 <sup>15</sup>Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia

38 <sup>16</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston,  
39 TX, 77030, USA.

40 <sup>17</sup>Baylor Genetics, Houston, TX, 77021, USA.

41 <sup>18</sup>Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of  
42 Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, United  
43 Kingdom

44 <sup>19</sup>NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon  
45 Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK

46

47 \*To whom correspondence should be addressed. Tel: +61-3-8344-8317 Email:  
48 [daniella.hock@unimelb.edu.au](mailto:daniella.hock@unimelb.edu.au) (Daniella H. Hock) Tel: +61-3-8341-6235 Email:  
49 [david.thorburn@mcri.edu.au](mailto:david.thorburn@mcri.edu.au) (David R. Thorburn); Tel: +61-3-8344-7316; Email:  
50 [david.stroud@unimelb.edu.au](mailto:david.stroud@unimelb.edu.au) (David A. Stroud).

51

52 \*\*MitoMDT Diagnostic Network for Genomics and Omics members are listed at the end  
53 of the manuscript.

54

## 55 **Abstract**

56 Only half of individuals with suspected rare diseases receive a definitive genetic diagnosis  
57 following genomic testing. A genetic diagnosis allows access to appropriate patient care  
58 and reduces the number of potentially unnecessary interventions and related healthcare  
59 costs. Here, we demonstrate that an untargeted quantitative mass-spectrometry  
60 approach quantifying >6,000 proteins in primary fibroblasts representing >80% of known  
61 mitochondrial disease genes can provide functional evidence for 83% of individuals in a  
62 cohort of known primary mitochondrial diseases. We profiled >90 individuals, including  
63 28 with confirmed disease and diagnosed 6 individuals with variants in both nuclear and  
64 mitochondrial genes. Lastly, we developed an ultra-rapid proteomics pipeline using  
65 minimally invasive peripheral blood mononuclear cells to support upgrade of variant  
66 pathogenicity in as little as 54 hours in critically ill infants with suspected mitochondrial  
67 disorders. This study supports the integration of a single untargeted proteomics test into  
68 routine diagnostic practice for the diagnosis of rare genetic disorders in clinically

69 actionable timelines, offering a paradigm shift for the functional validation of genetic  
70 variants.

71

## 72 ***Introduction***

73 Despite advances in genomic sequencing approaches, only 35-70% of individuals with  
74 suspected rare disease receive a molecular diagnosis following whole exome sequencing  
75 (WES) or whole genome sequencing (WGS)<sup>1-5</sup>. Negative cases generally remain  
76 undiagnosed due to variants being refractory to short-read sequencing approaches or  
77 when detected variants of uncertain significance (VUS, Class 3) are detected, requiring  
78 functional evidence to be upgraded to likely pathogenic (Class 4) or pathogenic (Class 5).  
79 Mitochondrial disease is an umbrella term for a group of over 300 rare monogenic  
80 disorders affecting mitochondrial energy production in the form of ATP<sup>6</sup>. These disorders  
81 can arise from sporadic or inherited variants in either nuclear or mitochondrial DNA  
82 (mtDNA), presenting at any stage of life with a myriad of symptoms affecting either a  
83 single organ or in a multisystemic manner<sup>7</sup>. Mitochondrial diseases affect approximately  
84 1 in 5,000 live births<sup>8</sup> with limited treatments available, reinforcing the importance of a  
85 genomic diagnosis for early intervention in affected individuals. A genomic diagnosis also  
86 facilitates informed reproductive options such as prenatal diagnosis (PND) and assisted  
87 reproductive technologies such as preimplantation genetic testing (PGT) and  
88 mitochondrial replacement therapy (MRT)<sup>9</sup>.

89 Functional approaches to assess VUS pathogenicity in mitochondrial disease have  
90 historically relied on targeted and low throughput tests such as respiratory chain  
91 enzymology (RCE), SDS-polyacrylamide gel electrophoresis (PAGE) or Blue Native (BN)-  
92 PAGE and immunoblotting. RCE assesses the activity of the mitochondrial respiratory  
93 chain complexes I-IV and is typically normalised to the activity of a single enzyme, citrate  
94 synthase (CS), to account for variability in mitochondrial content determined by sample  
95 quality, amount and storage<sup>10</sup>. Western blotting has also been used for the confirmation  
96 of VUS pathogenicity based on protein abundance or differential size, although it relies  
97 on having a strong genetic lead for disease causation from genomic data and the  
98 commercial availability of antibodies for the desired protein.

99 Other non-targeted functional approaches such as transcriptomics and proteomics have  
100 also been applied to the diagnosis of mitochondrial diseases. In selected cohorts,  
101 transcriptomics has been shown to increase the diagnosis of mitochondrial disorders by  
102 10-16%<sup>11, 12</sup> and other rare Mendelian disorders by 7-17%<sup>13-15</sup>. Although transcriptomic  
103 analysis can be a powerful tool in assessing pathogenicity of intronic and splice variants,  
104 this approach has limited power in offering functional information on missense variants,  
105 one of the most common and challenging classes of variants to assess<sup>16, 17</sup>. Splice  
106 variants are predicted to account for only 10% of pathogenic variants associated with  
107 autosomal recessive disorders<sup>18</sup>, in line with current diagnostic rates achieved by  
108 transcriptomics. Missense variants, on the other hand, account for 60% of pathogenic  
109 variants<sup>18</sup> and approximately 40% of them are expected to result in reduced protein levels  
110 due to protein instability and turnover<sup>19</sup>. Proteomics can detect such changes and has  
111 been demonstrated to contribute to the diagnosis of Mendelian disorders by providing  
112 functional evidence for not only missense variants but also splice, deep intronic and copy  
113 number variants<sup>11, 20-25</sup>. Despite this, there is a lack of data to inform the general utility of  
114 proteomics in rare disease diagnoses as an untargeted approach like genomics and  
115 transcriptomics.

116 Here, we present a systematic analysis demonstrating the utility of proteomics in the  
117 detection of rare mitochondrial disorders and provide the first validated pipeline for ultra-  
118 rapid functional testing using peripheral blood mononuclear cells (PBMCs). Reference  
119 proteomics data and associated bioinformatics tools for performing the proteome analysis  
120 approaches developed for these investigations can be applied to user-uploaded data  
121 through our interactive web tool (<https://rdmassspec.shinyapps.io/RDMSExplorer/>).

122


## 123 **Results**

124 To validate our untargeted proteomic approach in the detection of mitochondrial disorders,  
125 we first analysed primary fibroblast cell lines from a cohort of 24 patients with confirmed  
126 genetic diagnoses based on known pathogenic or likely pathogenic nuclear or mtDNA-  
127 encoded variants. This validation cohort (VC) included cell lines with defects in subunits  
128 or assembly factors for each of the five individual OXPHOS complexes as well as defects  
129 of mtDNA translation that impact multiple complexes, causing a combined OXPHOS

130 biochemical defect (**Fig 1A, Supplementary Table 1**). Principal component analysis  
131 showed that proteomes segregate according to their primary defect (**Fig. 1B**) and  
132 hierarchical clustering of OXPHOS subunits and assembly factors identified clear profiles  
133 (**Supplementary Fig. 1A, B**). We have previously shown similar profiles to be present in  
134 gene-edited HEK293T knockout of Complex I subunits<sup>26</sup>. Comparison of mitochondrial  
135 proteomes from our validation cohort of fibroblast cell lines and corresponding gene-  
136 edited HEK293T knockout cell lines (knockout cohort, KC) showed good correlation of  
137 dysregulated proteins (**Supplementary Fig. 2A, B**).

138  
139 The maximum theoretical coverage of known mitochondrial disease gene products from  
140 the fractionated library was 80%, with a routine coverage of 64% in a standard 95-minute  
141 library-supported DIA run from fibroblast samples (**Fig. 1C**). Our approach could also  
142 detect proteins corresponding to 37% of the Mendeliome (i.e., encoded by known disease  
143 genes) in a standard 95-minute run, supporting the potential utility of proteomics as a  
144 disease agnostic test in the resolution of many rare monogenic disorders. In terms of  
145 variant type in the validation cohort, the most common type was nuclear single nucleotide  
146 variants (48%) followed by mtDNA single nucleotide variants (16%), indel (16%), splice  
147 site (13%) and deep intronic (6%) (**Fig. 1D**). We quantified the abundance of the protein  
148 of interest in 67% of our investigations with the most common outcome being the protein  
149 abundance readily quantified in controls and absent in proband (42%) followed by a  
150 decrease in the patient relative to controls (21%) (**Fig. 1E**). In 29% of cases the protein  
151 of interest was not detected in either proband or control fibroblasts. For the cases where  
152 the protein was identified in both proband and control fibroblasts, analysis of the standard  
153 deviation show that ND1 abundance in VC6 (*MT-ND1*) was 97% relative to control median  
154 and within the control distribution, while ND5 abundance in VC12 (*MT-ND5*) was 118%  
155 relative to control median and approximately 3 standard deviations above the control  
156 median (**Fig. 1F**). Other identified proteins were outside the control range and >9 standard  
157 deviations below control median (**Fig. 1F**).

158  
159



160

161 **Figure 1. Study design and validation cohort analysis** A – Quantitative proteomics experimental design  
 162 overview. A fibroblast validation cohort (VC), HEK293T knockout cohort (KC), undiagnosed patient cohort  
 163 (UDP) and supporting cohort (SC) prepared using S-Trap™ columns. Digested peptides were subjected to  
 164 Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) Data Independent Acquisition (DIA).  
 165 Pooled control peptides were fractionated using strong cation-exchange (SCX) chromatography and data  
 166 acquired as Data Dependent Acquisition (DDA) to generate spectral libraries for fibroblasts (Fbs), HEK293T  
 167 (HEK) and PBMcs. Raw data were searched using Spectronaut® software and data analyses were  
 168 performed with a combination of Perseus software, Python and R. **B** – Principal Component Analysis (PCA)  
 169 of the fibroblast validation cohort (N=24) relative to controls based on the differential abundance of whole  
 170 cell proteins calculated from t-test. **C** – Venn diagram showing the coverage of Mendeliome (v. 0.12869,  
 171 top panel) and Mitochondrial disease (v. 0.787, bottom panel) lists including green (diagnostic-grade)  
 172 and amber (borderline diagnostic-grade) genes retrieved from PanelApp Australia<sup>27</sup>. **D** – Summary of the  
 173 genetic variant types analysed in the validation cohort (VC). **E** – Summary of the findings in the VC based  
 174 on protein identification and abundance. In 42% (10/24) of the cases the protein expected to be affected by  
 175 the genetic variant is not detected in the patient while it is detected in the controls. In 29% (7/24) of the  
 176 cases, the protein is not detected via quantitative proteomics, in 21% (5/24) of the cases, the protein is  
 177 decreased in abundance in the patient compared to the 5 controls, and in 4% (1/24) of the cases, the protein



178 is increased compared to the controls analysed. SNV = single nucleotide variant. **F** – Protein standard  
179 deviation from control median of the respective affected gene in controls (purple) and probands (red) in the  
180 validation cohort (VC). Standard deviation was calculated from the median control variance.

181  
182 Mitochondrial content has previously been calculated in proteomics data using the mean  
183 abundance of experimentally validated mitochondrial proteins in the MitoCarta 3.0  
184 database<sup>28, 29</sup>. We noticed that the mean abundance of mitochondrial proteins as a group  
185 varied between cell lines in our validation cohort (**Supplementary Fig. 3A**) but not control  
186 individuals (**Supplementary Fig. 3B**). This phenomenon is typically taken into  
187 consideration in enzymology analyses by expressing enzyme rates as citrate synthase  
188 (CS) ratios to account for mitochondrial proliferation or cell/tissue variability<sup>10, 30</sup>. CS  
189 enzyme activity in our validation cohort varied greatly (**Supplementary Fig. 3A, upper**  
190 **panel**), consistent with altered mitochondrial content. Surprisingly, while CS activity did  
191 have a weak positive correlation with the relative abundance of CS protein as detected  
192 by proteomics (**Supplementary Fig. 3C, left panel**), it did not correlate with mitochondrial  
193 content calculated from the abundance of mitochondrial proteins (**Supplementary Fig.**  
194 **3C, middle panel**). In line with this, CS protein abundance also did not correlate with  
195 mitochondrial content calculated from proteomics data (**Supplementary Fig. 3C, right**  
196 **panel**). Since the nature of proteomics-based RCA is relative protein abundance, we  
197 concluded that mean mitochondrial protein abundance is the appropriate metric to  
198 normalise proteomics data. We built a differential mitochondrial abundance correction  
199 step into our RCA calculations (see **Materials and Methods** for detailed information).  
200 This correction is of benefit for cell lines that may have different mitochondrial content to  
201 controls and corrects for mitochondrial content before calculating the relative abundance  
202 of each complex.

203  
204 We next sought to systematically benchmark our RCA analysis against clinical RCE. RCE  
205 was performed on 23 of the 24 fibroblast lines in the validation cohort, and was also  
206 performed on skeletal muscle (SKM) or lymphoblastoid cell lines (LCLs) for 17 of the 24  
207 patients. Results are presented relative to CS (**Supplementary Table 2**) and the Bernier  
208 criteria<sup>31</sup> were used to classify results. Fibroblast RCE detected a definite defect (<30%,  
209 major criterion) in the expected complex(es) for 19 of 24 fibroblast lines (79%) while three

210 [VC4 (*NDUFS2*), VC7 (*NDUFAF1*) and VC10 (*NDUFB10*)] had a probable defect (minor  
211 criterion) and RCE did not detect a defect in VC19 (*COX6B1*) fibroblasts (**Fig. 2A left**  
212 **panel, Supplementary Table 2**). When skeletal muscle or LCLs were also available,  
213 RCE revealed a major defect in 9 of 17 of the analyses (53%), and a minor defect in four  
214 (23%) while three were not deficient (18%) and one was not available (6%)(**Fig. 2A, right**  
215 **panel**).

216  
217 Relative complex abundance (RCA) analysis was performed incorporating the correction  
218 for mitochondrial content (**Supplementary Fig. 4**) as described above. We classified a  
219 major defect as an RCA abundance  $\leq 65\%$  relative to controls or  $\leq 75\%$  with absent  
220 detection of the protein of interest in the proband with  $>2$  peptides detected in controls  
221 while minor defects were classified by an RCA abundance of  $\leq 75\%$  relative to controls  
222 (**Supplementary Table 2**). Using these criteria, a major RCA defect was detected in 83%  
223 of the cell lines in the validation cohort, a minor defect in a single case, VC19 (*COX6B1*),  
224 and no defect was detected in three cell lines with mtDNA variants (**Fig. 2B**). Overall,  
225 there is no strong correlation between RCE activity and an RCA value relative to control  
226 ( $R=0.072$ ,  $p=0.78$ ) (**Fig. 2C**).


227  
228 For isolated Complex I disorders, 83% (10/12 patients) had a complex I abundance lower  
229 than 75% relative to controls analysed ( $p<0.0001$ ). Two of the three Complex I-deficient  
230 fibroblast lines harbouring missense mtDNA-encoded variants were refractory to RCA  
231 analysis but diagnostic by RCE. mtDNA variant heteroplasmy in fibroblasts was 92% for  
232 VC6 *MT-ND1* and 71% for VC12 *MT-ND5*, highlighting a limitation of our approach in the  
233 detection of some mtDNA-driven disorders. Importantly, in all 10 fibroblast lines where  
234 RCA was diagnostic for a Complex I disorder, lower abundance ( $<65\%$  relative to  
235 controls) of Complexes III, IV and V were not noted (**Supplementary Fig. 4**). While  
236 Complex II was reduced to  $<75\%$  in four of these, RCE similarly identified a probable  
237 Complex II defect for one (*FOXRED1*), supporting the accuracy and specificity of RCA  
238 analysis. In 7/7 individuals with isolated Complex II, III or IV disorders, the abundance of  
239 the relevant complex was reduced to  $<75\%$  controls (**Fig. 2D**) however t-test significance  
240 varied, especially in CII and IV defects where the number of detected subunits was as



241 low as two. All were specific for the relevant isolated defect except for *UQCRC2* where a  
242 Complex I abundance of 67% control ( $p < 0.0001$ ) was noted, as expected for Complex III  
243 disorders<sup>32</sup>.

244  
245 For isolated disorders involving Complexes I-IV due to nuclear defects, we determine an  
246 RCA value in fibroblasts of <65% controls to be diagnostic. The same threshold may also  
247 be applied to isolated disorders caused by pathogenic variants in mtDNA including those  
248 leading to Complex V deficiency, however smaller reductions may not exclude  
249 pathogenicity as seen in VC6 (*MT-ND1*), VC12 (*MT-ND5*) and VC20 (*MT-ATP6*) (**Fig.**  
250 **2D**). Interestingly, in the case of VC6 this was likely not due to heteroplasmy, which was  
251 92% NC\_012920.1(*MT-ND1*):m.3949C>T in fibroblasts. On the other hand, in VC12 the  
252 NC\_012920.1(*MT-ND5*):m.13513G>A variant found at 71% in fibroblasts, did not show  
253 the expected RCA defect while it satisfied the major criteria in RCE (**Supplementary**  
254 **Table 2**), suggesting impaired enzyme kinetics in the absence of a structural Complex I  
255 defect. Finally, we found that defects directly impacting mitochondrial translation such as  
256 *MRPS34* fibroblasts presenting with a destabilised mitochondrial ribosome small  
257 subunit<sup>25</sup>, *MT-TK* which encodes the mitochondrial lysine transfer RNA<sup>33</sup>, *MTFMT* which  
258 encodes the mitochondrial methionyl-tRNA formyltransferase<sup>34</sup>, and *FARS2* encoding  
259 mitochondrial phenylalanyl-tRNA synthetase, led to combined Complex I and IV defects  
260 that each met criteria of an RCA value <65% control (**Fig. 2D**), consistent with the major  
261 criterion observed in RCE (**Supplementary Table 2**). Taken together, fibroblast RCA  
262 detected an OXPHOS defect at <65% relative to controls in the expected complex(es) for  
263 20 of 24 fibroblast lines tested (83%) (**Fig. 2B**). One fibroblast line, VC19 (*COX6B1*), had  
264 an RCA of 71% for Complex IV relative to controls, which is in line with a previous report  
265 showing remaining assembled complex<sup>35</sup> and the peripheral position of the late  
266 assembled COX6B1 subunit in the structure of Complex IV<sup>36, 37</sup>. Three fibroblast lines  
267 where a definitive defect was not observed by RCA harboured variants in mtDNA,  
268 suggesting that this class of variant may be more refractory to RCA analysis. Despite this,  
269 proteomics-based RCA outperformed RCE in the detection of primary mitochondrial  
270 disease. It is important to note here that the nature of proteomics as an untargeted  
271 approach means that additional analyses can be performed from the same proteomic

272 data, such as reduced abundance of specific proteins encoded by the gene of interest  
 273 (**Fig. 1E, F**) and co-dependent proteins in structural modules (**Supplementary Fig. 1B**).  
 274 This is exemplified in the VC2 (*NDUFS6*) case where despite showing a Complex I  
 275 abundance of 74%, topographical mapping of Complex I subunit abundances against the  
 276 cryo-EM structure show specific reduction of the N-module of Complex I, providing strong  
 277 evidence in supporting disease causation.



278  
 279 **Figure 2. Proteomics outperforms clinical respiratory chain enzymology in detection of**  
 280 **mitochondrial disorders** **A** – (left) Summary of the RCE results in fibroblasts according to the Bernier  
 281 criteria<sup>31</sup>. (right) Summary of the RCE results in tissues (skeletal muscle, skm or lymphoblastoid cell line,  
 282 LCL) according to the Bernier criteria<sup>31</sup>. **B** – Summary of the RCA results from quantitative proteomic data.  
 283 **C** – Pearson correlation between RCA results and Respiratory Chain Enzymology results for Complexes I,  
 284 III and IV. **D** – RCA results of OXPHOS complexes from the validation cohort showing the predicted affected  
 285 complexes for each cell line. CI-V = Complex I-V. Tr. = translation. Middle bar represents mean complex  
 286 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a  
 287 paired t-test between the individual protein means. \*\*\*\* =  $p < 0.0001$ , \*\*\* =  $p < 0.001$ , \*\* =  $p < 0.01$ , \* =  $p < 0.05$ ,  
 288 ns = not significant,  $p > 0.05$ .

289

290 After benchmarking quantitative proteomics and RCA analysis against the validation  
291 cohort, we applied our label-free DIA method to six undiagnosed cases where primary  
292 fibroblast or skeletal muscle were available for proteomic analysis.

293

#### 294 **UDP1 (*MT-ATP6*)**


295 UDP1 (*MT-ATP6*) was a four-year-old child who had intrauterine growth retardation,  
296 truncal hypotonia, microcephaly, global developmental delay, left ventricular  
297 noncompaction and Wolff-Parkinson-White syndrome. Biochemically there was a  
298 marginal elevation of blood lactate (2.8 mmol/L; normal range 0.7 – 2.0) and 3-  
299 methylglutaconic aciduria. Missense variants were identified in *MT-ATP6*  
300 [NC\_012920.1(*MT-ATP6*):m.8672T>C;p.(Leu49Pro)], a *de novo* variant with 81%  
301 heteroplasmy in blood, and *ATAD3A* (heterozygous c.683C>T;p.Thr228Met) from WES  
302 plus mtDNA sequencing from blood and both classified as a VUS. Clinical RCE assays  
303 typically do not include Complex V activity and proteomics was sought to provide  
304 functional evidence. Despite proteomic RCA analysis showing no reduction in abundance  
305 of Complex V (104% relative to controls), there was a reduction in the number of Complex  
306 V subunits identified from 13 to 10 compared to the diagnosed *MT-ATP6* patient as well  
307 as other cases in the same batch (**Fig. 3A** and **Supplementary Fig. 4**). The Complex V  
308 subunits that are not detected in UDP1 (*MT-ATP6*) but are detected in VC20 (*MT-ATP6*)  
309 are ATP5IF1, the ATPase inhibitor, and ATP5MD (ATP5MK/DAPIT) and ATP5MPL  
310 (ATP5MJ/MP68/6.8PL), which like ATP6, are incorporated at a late stage in the assembly  
311 of Complex V<sup>36, 38</sup>. The latter suggests a specific turnover of late stage assembled  
312 subunits of Complex V below the limit of detection of proteomics in the proband, which  
313 contributes to the unchanged Complex V levels seen in the RCA of UDP1 (*MT-ATP6*).  
314 We processed the same data using q-value sparse run-wise imputation in the  
315 Spectronaut® that allows for peptides that were identified in one sample to be imputed at  
316 the limit of detection in samples where they were not detected. This allowed us to estimate  
317 the fold changes of ATP6 (*MT-ATP6*) and ATP5MPL proteins in UDP1 (*MT-ATP6*) and  
318 correlate their reduced levels with VC20 (*MT-ATP6*) as well as confirming unchanged  
319 levels of *ATAD3A* (**Fig. 3B**). Another data analysis strategy we explored for UDP1 (*MT-*  
320 *ATP6*) was the use of an *in-silico* library-free analysis including the protein sequence of

321 the ATAD3A variant p.Thr228Met. As expected, the peptide containing the methionine at  
322 position 228 was only detected in the patient (**Fig. 3C**) and present at ~43% of the  
323 abundance relative to the canonical peptide expressed from the other allele  
324 (**Supplementary Fig. 5A**). Taken together, these results suggest that the *MT-ATP6*  
325 p.Leu49Pro variant is the likely diagnosis for this case.

326

327 The lack of a Complex V defect in proteomics RCA analysis of both *MT-ATP6* cases  
328 (VC20 and UDP1) prompted us to analyse additional patients with known pathogenic  
329 variants affecting Complex V. Supporting cohort probands SC1 and SC2 were two  
330 unrelated infants presenting with lactic acidosis, cardiac abnormalities (persistent patent  
331 ductus arteriosus, ventriculo-septal defect and cardiomyopathy), mild dysmorphic facial  
332 features, hypospadias, hyperammonaemia and 3-methyl-glutaconic aciduria. Targeted  
333 gene sequencing based on this phenotype identified in both individuals a homozygous  
334 intronic founder variant NM\_017866.6(*TMEM70*):c.317-2A>G classified as Class  
335 5/pathogenic, with several patients previously reported<sup>39-43</sup>. Skeletal muscle samples  
336 were available for both cases and compared against three unrelated individuals using the  
337 library-free DIA approach. Whole muscle proteomic analyses showed reduction of several  
338 Complex V subunits in SC1 and SC2 respectively (**Fig. 3D** and **E**). RCA analyses  
339 quantified the relative abundance of Complex V at 19% and 20% (**Fig. 3F** and **G**),  
340 demonstrating that defects in Complex V can be detected using RCA analysis. *TMEM70*  
341 has also been implicated in Complex I assembly<sup>44, 45</sup>, although no defects in Complex I  
342 abundance were noted in these muscle samples.

343



344

345 **Figure 3. Proteomics supports the diagnosis of patients with suspected mitochondrial disorders. A**  
 346 – Relative Complex Abundance (RCA) of Complex V subunits in undiagnosed patient UDP1 (*MT-ATP6*)  
 347 and diagnosed VC20 (*MT-ATP6*) patient. Middle bar represents mean complex abundance. Upper and



348 lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the  
349 individual protein means. ns = not significant,  $p > 0.05$ . **B** – Correlation between  $\log_2$  fold-changes from  
350 whole-cell proteins from run-wise imputed data between undiagnosed patient UDP1 (*MT-ATP6*) and  
351 diagnosed patient VC20 (*MT-ATP6*) harbouring mutations in *MT-ATP6* and controls showing reduced  
352 abundance in late assembly proteins, MT-ATP6 and ATP5MPL, for both patients. **C** – Spectral intensity of  
353 the peptide containing the ATAD3A p.Thr228Met variant detected in the UDP1 patient but not in controls.  
354 **D** – Volcano plot of whole cell proteins from SC1 (*TMEM70*) whole-cell skeletal muscle compared to controls  
355 (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent  $\pm 2$ -fold-  
356 change equivalent and horizontal lines represent significance  $p$ -value  $\leq 0.05$  equivalent from a two-sample  
357 t-test. **E** – Volcano plot of whole cell proteins from SC2 (*TMEM70*) whole-cell skeletal muscle compared to  
358 controls (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent  
359  $\pm 2$ -fold-change equivalent and horizontal lines represent significance  $p$ -value  $\leq 0.05$  equivalent from a two-  
360 sample t-test. **F** – Relative Complex Abundance (RCA) of OXPHOS subunits in undiagnosed patient SC1  
361 (*TMEM70*). Middle bar represents mean complex abundance. Upper and lower bars represent 95%  
362 confidence interval. Significance was calculated from a paired t-test between the individual protein means.  
363 \*\*\*\* =  $p < 0.0001$ , \*\*\* =  $p < 0.001$ , \* =  $p < 0.05$ , ns = not significant,  $p > 0.05$ . **G** – Relative Complex Abundance  
364 (RCA) of OXPHOS subunits in undiagnosed patient SC2 (*TMEM70*). Middle bar represents mean complex  
365 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a  
366 paired t-test between the individual protein means. \*\*\*\* =  $p < 0.0001$ , \*\*\* =  $p < 0.001$ , \*\* =  $p < 0.01$ , \* =  $p < 0.05$ .  
367 **H** – Volcano plot of whole cell proteins from UDP4 (*CCDC47*) fibroblasts compared to controls showing  
368 reduced abundance of *CCDC47*. No significant changes to Complex V proteins (orange). Vertical lines  
369 represent  $\pm 2$ -fold-change equivalent and horizontal lines represent significance  $p$ -value  $\leq 0.05$  equivalent  
370 from a two-sample t-test. **I** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP4  
371 (*CCDC47*) fibroblasts compared to controls. \* =  $p < 0.05$ , ns = not significant,  $p > 0.05$ . **J** – Volcano plot of  
372 whole cell proteins from UDP5 (*NDUFA10*) fibroblasts compared to controls showing reduced abundance  
373 of *NDUFA10* and other structural subunits of Complex I. Vertical lines represent  $\pm 2$ -fold-change equivalent  
374 and horizontal lines represent significance  $p$ -value  $\leq 0.05$  equivalent. Blue = Complex I subunits. **K** –  
375 Relative Complex Abundance (RCA) of OXPHOS complexes from UDP5 (*NDUFA10*) fibroblasts compared  
376 to controls (N=4) showing isolated Complex I defect. Middle bar represents mean complex abundance.  
377 Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test  
378 between the individual protein means. \*\*\*\* =  $p < 0.0001$ , \* =  $p < 0.05$ , ns = not significant,  $p > 0.05$ . **L** –  
379 *NDUFA10* and *HIBCH* protein abundance from two-sample t-test in SC3, a confirmed *HIBCH* proband and  
380 UDP5 (*NDUFA10*) whole-cell fibroblasts compared to controls showing an approximate half reduction in  
381 *HIBCH* levels in UDP5 (*NDUFA10*, *HIBCH* carrier) compared to SC3 and unchanged *NDUFA10* levels in  
382 SC3. **M** – Timeline for the rapid proteomics from live fibroblast sample receipt to results for UDP5  
383 (*NDUFA10*) case achieved in less than five days.

384

### 385 **UDP4 (*CCDC47*)**

386 UDP4 (*CCDC47*) was born to consanguineous parents, presenting with intrauterine  
387 growth restriction, severe failure to thrive, short stature, hypotonia, marked developmental  
388 delay, mildly dysmorphic features, severe pruritus woolly hair and increased plasma bile  
389 acids (224  $\mu\text{mol/L}$ ; normal range  $< 7$ ), Ricketts and decreased mitochondrial CIII activity  
390 in liver and muscle<sup>46</sup>. WES performed on DNA extracted from fibroblasts and analysed  
391 using a mitochondrial disease gene panel identified single heterozygous missense



392 variants NM\_001358921.2(COQ2):c.460G>C; p.(Gly154Arg) and  
393 NM\_020312.4(COQ9):c.826C>T p.(Arg276Trp). Suspecting a compound oligogenic  
394 mechanism impacting Coenzyme Q biosynthesis, RCA analysis was performed on  
395 fibroblast cells. No abundance changes to COQ9 or respiratory chain complexes I-IV  
396 were identified, although an abundance of 84% in Complex V was noted (**Fig. 3H** and **I**).  
397 This reduction was regarded as not biologically significant as no rare variants in Complex  
398 V related genes were flagged from sequencing data. Transcriptomic analysis performed  
399 in RNA extracted from skeletal muscle showed a reduced abundance of *CCDC47*  
400 transcript (**Supplementary Fig. 5B**). Re-analysis of proteomics data was sought to  
401 provide functional evidence to support the transcriptomic findings, which confirmed a  
402 reduction in the abundance of *CCDC47* in primary fibroblasts from imputed data (**Fig. 3H**).  
403 Re-analysis of sequencing data identified a homozygous variant  
404 NM\_020198.3(*CCDC47*):c.431C>G;p.(Thr144Asn). SpliceAI predicted ( $\delta$  score 0.964)  
405 the activation of a donor-splice site five nucleotides upstream of this variant, and PCR  
406 analysis of the muscle cDNA showed the presence of both the missense transcript and a  
407 second shorter one, missing 121 bp from the 3' end of exon 4 resulting in a loss-of-  
408 function type transcript p.(Val143Glyfs\*15) (**Supplementary Fig. 5C**). This variant is not  
409 observed in the gnomAD population database nor any clinical cases previously but is  
410 predicted to be classified as likely pathogenic/Class 4, supported by the observed splicing  
411 defect, as well as reduced abundance in *CCDC47* transcript and *CCDC47* protein levels.  
412 *CCDC47* has been previously linked to Trichohepatoneurodevelopmental Syndrome<sup>47</sup>  
413 (MIM 618268) which presents an overlapping phenotype to *UDP4* (*CCDC47*). The  
414 observed reduction in *CCDC47* transcripts due to incorrect splicing is in keeping with  
415 previously reported patients, all of whom harbour loss-of-function variants<sup>47, 48</sup>.

416

#### 417 **UDP5 (*NDUFA10*)**


418 UDP5 presented with nystagmus, hypotonia, vomiting and weight loss at 20 weeks of age.  
419 She had lactic acidosis, concentric left ventricular hypertrophy with 48% ejection fraction,  
420 T2 hyperintense lesions in the substantia nigra and passed away at 24 weeks of age.  
421 Targeted exome sequencing analysis flagged candidate variants  
422 NM\_004544.4(*NDUFA10*):c.914T>C; p.(Leu305Pro) homozygous VUS/Class 3,

423 NM\_014362.4(*HIBCH*):c.891+1G>A, heterozygous likely pathogenic/Class 4 and  
424 NM\_018292.5(*QRSL1*):c.22G>C, p.(Glu8Gln) heterozygous VUS/Class 3. Fibroblast  
425 proteomics detected *NDUFA10* and *HIBCH* below 2-fold-change (representing >50%  
426 reduction) in the patient relative to controls (**Fig. 3J and Supplementary Figure 5D**).  
427 *QRSL1* level was slightly increased but not significant, which led us to further investigate  
428 *NDUFA10* and *HIBCH* leads. *NDUFA10* is a structural subunit of Complex I and additional  
429 functional evidence for pathogenicity could be drawn from reduced abundance of other  
430 Complex I subunits, with RCA analysis quantifying Complex I abundance at 43% in UDP5  
431 (*NDUFA10*) compared to controls, meeting the criteria for a major defect (**Fig. 3K**). We  
432 further assessed whether the levels of *HIBCH* protein were compatible with a carrier  
433 (heterozygous) state by analyzing fibroblasts from an unrelated patient (SC3) diagnosed  
434 with bi-allelic pathogenic variants: NM\_014362.4(*HIBCH*):c.891+1G>A &  
435 NM\_014362.4(*HIBCH*):c.470G>A; p.(Arg157Gln). Proteomic results show that *HIBCH*  
436 protein in SC3 (*HIBCH*) is almost two times less abundant than in UDP5 (*NDUFA10*) (**Fig.**  
437 **3L, left panel**) while the levels of *NDUFA10* protein were unchanged in SC3 (*HIBCH*),  
438 suggesting that a reduction in *NDUFA10* is not a secondary defect from a primary *HIBCH*  
439 defect (**Fig. 3L right panel**). The lack of any decrease in Complex I in SC3 (*HIBCH*)  
440 suggests that the phenotype in UDP5 (*NDUFA10*) is likely to have arisen from the  
441 *NDUFA10* variant while the *HIBCH* variant is expressed as a carrier and further  
442 investigation for a second missed variant in *HIBCH* was not undertaken. UDP5 was the  
443 first child of non-consanguineous parents of Māori ethnicity. The mother was 6 weeks  
444 pregnant with a second child at the time of analysis and the family sought prenatal genetic  
445 testing (PGT). With this in mind, we prioritised sample processing and analysis, and were  
446 able to return results in less than 4 days from receipt of fibroblasts (**Fig. 3M**) with the  
447 results sufficient to support the upgrade of the *NDUFA10* variant c.914T>C;  
448 p.(Leu305Pro) to likely pathogenic/Class 4. This facilitated PGT, which confirmed  
449 absence of the *NDUFA10* variant, allowing continuation of the pregnancy and delivery of  
450 a healthy child who, at the time of writing, is 15-months old.

451  
452 The rapid turnaround time (TAT) in this case was only possible as fibroblasts from UDP5  
453 were available for analysis at the time of proteomics testing. Establishing and culturing a

454 new fibroblast line typically takes up to ~2 months and requires a skin biopsy<sup>49</sup> which is  
455 increasingly considered invasive and can potentially delay a diagnosis. We sought to  
456 explore the feasibility of rapid proteomics-based testing for suspected mitochondrial  
457 disorders using peripheral blood mononuclear cells (PBMCs), which can be readily  
458 obtained from whole blood and have been used in various diagnostic functional testing  
459 approaches previously. To test the applicability of PBMCs in proteomic testing we first  
460 generated a fractionated spectral library and compared it against the fibroblast spectral  
461 library and coverage of Mendeliome proteins (**Fig. 4A**). The PBMC library was generated  
462 from peptides of 39 normal individuals aged 0-17 years of age and can be used to  
463 confidently identify 8,016 gene products, including 52% of known Mendeliome genes<sup>27</sup>.  
464 In comparison, our fibroblast spectral library covers 8,305 genes and 55% of the  
465 Mendeliome. We performed a Principal Component Analysis (PCA) of whole-cell proteins  
466 in the 37 PBMC samples showing that over 99% of the proteins are tightly clustered at  
467 the whole-cell level and over 97% at the mitochondrial level (**Fig. 4B**).

468  
469 Next, we validated the use of PBMCs against fibroblasts by analysing both sample types  
470 from a diagnosed patient with pathogenic variants in *MRPL50* (Twin 2 in <sup>21</sup>, SC4 and  
471 SC5). *MRPL50* is a structural subunit of the mitoribosome<sup>50</sup> and defects in this subunit  
472 lead to impaired assembly of the large mitoribosomal subunit (mtLSU)<sup>21</sup>. We performed  
473 a correlation of the log<sub>2</sub> fold-change levels of mitochondrial proteins identified in both  
474 samples relative to controls which showed reduced abundance of multiple proteins  
475 belonging to the mtLSU in both sample types (**Fig. 4C**). RCA quantified the abundance  
476 of the mtLSU in 63% and 48% in PBMCs and fibroblasts respectively (**Supplementary**  
477 **Fig. 5E**).



478  
479  
480  
481

**Figure 4. Utility of ultra-rapid proteomics supports the diagnosis of critically ill infants with suspected mitochondrial disorders** A – Venn diagram showing the coverage of Mendeliome genes (PanelApp Australia Green and Amber entries, 4,264 genes) in the fibroblast spectral library (55% of

482 Mendeliome list of genes) and PBMC library (52% of Mendeliome list of genes). **B** – Principal Component  
483 Analysis (PCA) of the pilot PBMC normative data (N=36) for whole-cell proteins (top panel) and  
484 MitoCarta3.0 proteins (lower panel). **C** – Scatter plot showing the correlation between PBMC (SC4) and  
485 fibroblast (SC5) samples based on log<sub>2</sub> fold-changes from whole-cell proteins in a diagnosed patient with  
486 variants in *MRPL50* relative to controls<sup>21</sup> showing reduced abundance of the proteins belonging to the large  
487 subunits of the mitochondrial ribosome (mtLSU; purple), mtSSU = mitoribosome small subunit (orange).  
488 **D** – Volcano plot of whole cell proteins from UDP6 (*NDUFA13*) PBMCs compared to controls (N=5) showing  
489 reduced abundance of *NDUFA13* (orange dot) and other structural subunits of Complex I. Vertical lines  
490 represent  $\pm 2$ -fold-change equivalent and horizontal lines represent significance p-value  $\leq 0.05$  equivalent.  
491 Blue = Complex I subunits. **E** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP6  
492 (*NDUFA13*) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar  
493 represents mean complex abundance. Upper and lower bars represent 95% confidence interval.  
494 Significance was calculated from a paired t-test between the individual protein means. \*\*\*\* = p<0.0001, \* =  
495 p<0.05, ns = not significant, p>0.05. **F** – Protein range for *NDUFA13* in PBMCs in UDP6 (*NDUFA13*, red  
496 dot) and controls (N=5, purple dots) showing standard deviation of -12.2 from the control median. **G** –  
497 Volcano plot of whole cell proteins from UDP7 (*NDUF6*) PBMCs compared to controls (N=5) showing  
498 reduced abundance of *NDUFS8* and other structural subunits of Complex I. Vertical lines represent  $\pm 2$ -  
499 fold-change equivalent and horizontal lines represent significance p-value  $\leq 0.05$  equivalent. Blue =  
500 Complex I subunits. **H** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP7  
501 (*NDUF6*) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar  
502 represents mean complex abundance. Upper and lower bars represent 95% confidence interval.  
503 Significance was calculated from a paired t-test between the individual protein means. \*\*\*\* = p<0.0001, \*\*  
504 = p<0.01, ns = not significant, p>0.05. **I** – Timeline for ultra-rapid proteomics from PBMC sample receipt to  
505 results for UDP8 (*NDUFS8*) case achieved in less than 3 business days. **J** – Volcano plot of whole cell  
506 proteins from UDP7 (*NDUFS8*) PBMCs compared to controls (N=5) showing reduced abundance of  
507 *NDUFS8* protein (orange dot) and other structural subunits of Complex I. Vertical lines represent  $\pm 2$ -fold-  
508 change equivalent and horizontal lines represent significance p-value  $\leq 0.05$  equivalent. Blue = Complex I  
509 subunits. **K** – Relative Complex Abundance (RCA) of OXPHOS complexes from UDP8 (*NDUFS8*) PBMCs  
510 compared to controls (N=5) showing isolated Complex I defect. Middle bar represents mean complex  
511 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a  
512 paired t-test between the individual protein means. \*\*\*\* = p<0.0001, \*\* = p<0.01, \* = p<0.05, ns = not  
513 significant, p>0.05. **L** – Protein range for *NDUFS8* in PBMCs in UDP8 (*NDUFS8*, red dot) and controls (N=5,  
514 purple dots) showing standard deviation of -9.3 from the control median.

515

## 516 **UDP6 (*NDUFA13*)**

517 UDP6 (*NDUFA13*) presented at 2 years of age with chronic ataxia. She was the first child  
518 to non-consanguineous healthy parents from Iran and had a healthy 2-month-old brother.  
519 There was no family history of any neurological issues. She presented with chronic, stable  
520 ataxia, having been unsteady and falling frequently since she started walking at 14  
521 months of age. She had mild fine motor delay and a tremor. Her social, language, and  
522 cognitive development was age appropriate. On examination, UDP6 (*NDUFA13*) had  
523 normal growth parameters and was not dysmorphic. She had mild gait ataxia with a broad  
524 base. Her tone, power and reflexes were normal in upper and lower limbs bilaterally.



525 Ophthalmology examination was unremarkable. Magnetic resonance imaging (MRI) of  
526 brain showed bilateral symmetrical T2/FLAIR hyperintensity of the cerebral peduncles of  
527 the midbrain (and possibly the substantia nigra) and two symmetrical foci of high signal  
528 in the dorsal medulla with diffusion-weighted imaging (DWI) restriction. There were no  
529 basal ganglia or thalamic abnormalities. This was suggestive of a mitochondrial disorder.  
530 Serum blood lactate was elevated 2.4 (RR 1.0-1.8). Other metabolic investigations were  
531 normal. Audiology assessments and echocardiogram were normal. At 4 years of age, she  
532 has ongoing mild ataxia that improved with physiotherapy and was no longer falling. She  
533 has recently had deterioration in her vision and been diagnosed with optic neuropathy.  
534 Trio exome sequencing identified compound heterozygous variants  
535 NM\_015965.7(*NDUFA13*):c.170G>A; p.(Arg57His) likely pathogenic/Class 4 and  
536 NM\_015965.7(*NDUFA13*):c.187G>A; p.(Glu63Lys) VUS/Class 3. Proteomics was sought  
537 to provide functional evidence for the VUS/Class 3 variant and blood was collected for  
538 PBMC isolation as fibroblasts were not available at the time of analysis. Five unrelated  
539 PBMCs from age-matched normal donors were used as controls. A volcano plot showed  
540 reduction of *NDUFA13* protein and several other Complex I subunits in UDP6 (*NDUFA13*)  
541 (**Fig. 4D**) and RCA quantified the isolated Complex I defect at 47% control satisfying the  
542 criteria for a major defect (**Fig. 4E**). Analysis of the level of the *NDUFA13* protein in the  
543 proband demonstrated a residual abundance of 39%, which corresponds to greater than  
544 12 standard deviations below the control median (**Fig. 4F**). Proteomics data were  
545 subsequently used as functional evidence to upgrade the  
546 NM\_015965.7(*NDUFA13*):c.187G>A;p.(Glu63Lys) variant to likely pathogenic/Class 4.

547

#### 548 **UDP7 (*NDUFAF6*)**

549 UDP7 (*NDUFAF6*) was referred to the study at five months of age with asymmetric early  
550 onset growth restriction, central hypotonia, proximal renal tubular dysfunction, macrocytic  
551 anaemia, severe exocrine pancreatic insufficiency, liver dysfunction with cholestasis and  
552 mild persistent elevated lactate in CSF and blood. MRI showed symmetrical diffusion  
553 abnormality involving corticospinal tract, areas of brainstem and medial cerebellar  
554 hemisphere. He died at seven months of age due to progressive bulbar dysfunction with  
555 a probable clinical diagnosis of Leigh syndrome. Clinical trio WES identified a single



556 pathogenic (Class 5) heterozygous NM\_000262.3(*NAGA*):c.973G>A; p.(Glu325Lys)  
557 variant, and two *in trans* variants in *NDUFAF6*, a frameshift  
558 NM\_152416.4(*NDUFAF6*):c.267delT, p.(Tyr323Ilefs\*18) variant and a deep intronic  
559 variant, NM\_152416.4(*NDUFAF6*):c.298-768T>C, both classified as VUS/Class 3.  
560 PBMCs were the sample of choice due to lower invasiveness and potential for fast  
561 turnaround. Whole-cell proteomics identified no changes in the abundance of *NAGA*  
562 protein relative to controls (**Fig 4G**). *NAGA* encodes the alpha-N-  
563 acetylgalactosaminidase, a lysosomal enzyme whose deficiency causes a rare  
564 autosomal recessive lysosomal storage disorder. Previous reports of *NAGA*-deficiency  
565 show heterogenous presentations ranging from infantile-onset neuroaxonal dystrophy  
566 (Schindler disease type I, MIM [609241](#)) to an adult-onset disorder characterised by  
567 angiokeratoma corporis diffusum and mild intellectual impairment (Schindler disease type  
568 II, also known as Kanzaki disease MIM [609242](#))<sup>51</sup>. In addition to the proteomic studies,  
569 *UDP7* (*NDUFAF6*) did not appear to have clinical features consistent with *NAGA*-  
570 deficiency, and infants with this condition typically develop normally until about a year old.  
571 We then turned our investigations to *NDUFAF6* (*C8orf38*) which encodes an assembly  
572 factor involved in biogenesis of the core peripheral arm subunit *NDUFS8* of Complex I<sup>52</sup>  
573 and has previously been associated with the stability of the ND1 module of Complex I<sup>53</sup>.  
574 <sup>54</sup>. Previous reported cases of pathogenic variants in *NDUFAF6* present with a range of  
575 symptoms, including Leigh syndrome and the Acadian variant of Fanconi syndrome 5  
576 (proximal renal tubular dysfunction) (FRTS5, MIM 618913)<sup>53-57</sup>. *UDP7* (*NDUFAF6*) had  
577 clinical features consistent with Leigh syndrome, and while the aetiology of his liver  
578 dysfunction and severe exocrine pancreatic insufficiency was somewhat less clear, both  
579 would broadly fit with a mitochondrial cytopathy noting Complex I deficiencies often do  
580 not correlate perfectly with a single clinical subdivision. The  
581 NM\_152416.4(*NDUFAF6*):c.298-768T>C variant has been reported as likely pathogenic  
582 previously, specifically in relation to the FRTS5 phenotype<sup>56</sup>. A volcano plot from whole-  
583 cell PBMC proteomics data showed reduction in the abundance of several subunits of  
584 Complex I in *UDP7* (*NDUFAF6*), including *NDUFS8*, (**Fig. 4G**) with RCA analysis  
585 quantifying the isolated Complex I defect with a major defect of 34% relative to controls  
586 (**Fig. 4H**). Functional proteomic data and phenotype match support *NDUFAF6* as being

587 the causative gene for this clinical case, and the VUS/Class 3 variants are in the process  
588 of re-curation at the time of writing.

589

### 590 **UDP8 (*NDUFS8*)**

591 UDP8 (*NDUFS8*) was a neonate admitted to hospital presenting with persistent lactic  
592 acidemia, hypertrophic cardiomyopathy, left pulmonary artery stenosis, thickened  
593 pulmonary valve, hypotonia and microcephaly with progressive deterioration from 4 weeks  
594 of age, succumbing at 5 weeks of age. Brain MRI showed abnormalities in the corpus  
595 callosum and diffuse increased signal throughout the supratentorial white matter with  
596 small foci of gliosis in the peritrigonal regions. Ultra-rapid trio WGS identified a  
597 homozygous intronic variant NM\_002496.4(*NDUFS8*):c.501+5G>A with biparental  
598 inheritance. Due to the critical deteriorating condition, blood was collected from the  
599 proband and subjected to ultra-rapid proteomics. Five unrelated age-matched controls  
600 were used for comparison and the complete analysis was performed with a 54-hour  
601 turnaround time (TAT) from PBMC sample reception to the reporting of results to the  
602 clinical team (**Fig. 4I**). Whole-cell proteomic analysis of PBMCs showed significant  
603 reduction of several Complex I subunits, including *NDUFS8* (**Fig. 4J**) and RCA analysis  
604 showed an isolated Complex I defect with a major defect of 22% relative to controls (**Fig.**  
605 **4K**). Residual abundance of the *NDUFS8* protein in the proband was quantified at 20%,  
606 representing over 9 standard deviations below the control median (**Fig. 4L**). The strong  
607 phenotype match together with functional evidence from proteomics support disease  
608 causation due to variants in *NDUFS8* and leading to variant upgrade to likely  
609 pathogenic/Class 4.

610

### 611 **Discussion**

612 The estimated prevalence of rare disease in the population is in the range of 3.5-6%,  
613 equivalent to 263-446 million individuals worldwide<sup>58</sup>. There are over 7,000 different rare  
614 diseases known, with a current diagnostic yield of ~35-70% from WES or WGS<sup>1-5</sup>.  
615 Mitochondrial disease is a group of rare diseases caused by variants in over 300 known  
616 genes<sup>6, 16</sup>, where RCE has been historically performed to confirm a specific OXPHOS  
617 defect in the functional validation of variant pathogenicity<sup>16</sup>.

618

619 We have previously used an approach we term relative complex abundance (RCA) where  
620 proteomics data are used to quantify the residual abundance of OXPHOS complexes in  
621 clinical samples from individuals suspected of mitochondrial disease. We have shown  
622 that RCA acts as an effective proxy for clinically accredited RCE, including when  
623 appropriate samples have not been available<sup>20-22, 24, 25, 59-61</sup>. In an RCA analysis, the  
624 abundance of a complex in a sample is calculated from the mean of each individual  
625 subunit abundance detected by more than two peptides across each complex. The power  
626 of RCA analysis relies on the quantification of multiple peptides per protein in a complex  
627 with a high degree of subunit stability co-dependence, as we and others have previously  
628 shown for Complex I, III, IV, the mitoribosome<sup>11, 17, 20-22, 25, 59, 60, 62, 63</sup> and non-mitochondrial  
629 complexes such as the exocyst and nuclear pore complexes<sup>64, 65</sup>. RCE, on the other hand,  
630 typically relies on enzyme rate estimates determined in several replicates of patient  
631 samples and compared against age-matched controls. In some instances, we have found  
632 RCA demonstrated higher sensitivity by detecting a specific OXPHOS defect where RCE  
633 was inconclusive<sup>20, 22</sup>. RCA can also show higher specificity for use in functional validation  
634 of variant pathogenicity by detecting reduction of specific parts of the complex (e.g. loss  
635 of subunits in the catalytic Complex I N-module in VC1-*NDUFAF2* and VC2-*NDUFS6*),  
636 implicating only the 10 N-module subunits as candidate genes compared with loss of  
637 Complex I RCE potentially being caused by variants in any of more than 50 genes  
638 encoding Complex I subunits and assembly factors<sup>26, 66</sup>. In other cases, some variants  
639 encoded by the mtDNA resulted in no defect on RCA analysis despite over 70% and 90%  
640 heteroplasmy levels in fibroblasts. This suggests that some mtDNA variants can be  
641 refractive to RCA analysis due to an enzymatic and not a structural defect, where RCE  
642 might be an appropriate test to provide functional evidence. In terms of variant type,  
643 mitochondrial DNA variants account for only 0.54% of rare diseases while autosomal  
644 recessive variants account for over 41%<sup>67</sup> and are more likely to result in a loss-of-  
645 function protein<sup>68</sup>, which can be detected via quantitative proteomics.

646

647 RCE is typically performed on a tissue biopsy sample (e.g. skeletal muscle, liver) or  
648 primary cultured cells (e.g. fibroblasts). Establishing and growing primary fibroblasts from

649 skin biopsies to a sufficient volume of cells for RCE analysis involves weeks to months of  
650 cell culture<sup>49</sup>, and, in some cases, tissue specificity results in only mild or undetectable  
651 defects as measured by RCE<sup>10</sup>. Here we have demonstrated the feasibility of using  
652 PBMCs in diagnostic proteomics testing. In our hands, sufficient PBMCs for these  
653 analyses can be readily obtained from as a little as 1 ml of whole blood and the process  
654 from PBMC isolation to data acquisition performed in less than 48 hours. Together these  
655 properties and the results presented in this study demonstrate that PBMCs can be  
656 combined with our ultra-rapid proteomics pipeline for functional validation of variants  
657 causing defects in the mitochondrial OXPHOS system and the mitoribosome.

658  
659 The untargeted nature of quantitative proteomics also allows this technique to be applied  
660 beyond mitochondrial disease, as we have shown here for a mitochondrial disease  
661 phenocopy (UDP4; *CCDC47*) and elsewhere for nuclear pore, neuronal exocytic vesicle  
662 trafficking and rigid spine disorders<sup>64, 65, 69</sup>. Over 50% of known disease-associated  
663 genes<sup>27</sup> are routinely detected by our quantitative proteomics pipeline in PBMCs or  
664 fibroblasts, and over 45% of all disease genes listed in OMIM are part of a protein  
665 complex<sup>16</sup>. This means that pathogenic variants in one of these genes can lead to  
666 reduction of the protein of interest, which in some cases will result in downstream complex  
667 reduction as an additional layer of functional evidence to support variant upgrade. In  
668 terms of variant type, we show that quantitative proteomics can provide functional  
669 evidence for a wide range of genetic variants including CNV<sup>62</sup>, splice site and deep  
670 intronic<sup>20, 22</sup>, and missense variants<sup>21</sup>. Missense variants are the most common type of  
671 variant accounting for 60% of pathogenic variants associated with autosomal recessive  
672 disorders<sup>18</sup> and are usually refractory to transcriptomic analysis. For some cases,  
673 proteomics can also provide supportive functional evidence supportive when the protein  
674 encoded by the candidate gene is not detectable, either due to protein abundance being  
675 below the limit of detection or for genes encoding tRNAs, as seen in *VC22 (MT-TK)*,  
676 further expanding the potential application of proteomics in rare disease diagnosis.

677  
678 A genomics-first approach to rare disease diagnosis has markedly increased diagnostic  
679 rates and, in the case of rapid and ultra-rapid genomic testing, shortened diagnostic

680 odysseys to days instead of months<sup>65, 70-72</sup>. In the case of mitochondrial and many other  
681 rare diseases, diagnoses are often now achieved using just a blood sample, sparing many  
682 patients from an invasive biopsy of muscle or other tissues. As a result, diagnostic centres  
683 such as ours now receive a third or less of the number of samples for RCE testing than  
684 received 10 years ago. This provides an incentive for untargeted functional tests, such as  
685 RNA sequencing and proteomics, that could be financially viable and widely available in  
686 a pathology-certified context.

687  
688 This study also highlights the limitations of quantitative proteomics in detecting  
689 abundance changes in variants leading to catalytic defects and some mtDNA-encoded  
690 variants in fibroblasts. Moreover, the detection of proteins is related to the limit of  
691 detection as determined by the liquid chromatography, mass-spectrometry  
692 instrumentation, and data acquisition methods used. However, recent advances in mass-  
693 spectrometry instrumentation including development of the asymmetric track lossless  
694 (Astral) analyzer offer further improvements in sensitivity and greatly reduced run times<sup>73</sup>.  
695 Quantitative proteomics thus offers a further paradigm shift by providing functional  
696 evidence for variants in thousands of genes in a single test. This driver will facilitate the  
697 translation of proteomics testing for rare diseases into certified pathology laboratories.  
698 Clinically delivered proteomics can potentially replace hundreds of tests targeted to  
699 specific diseases, which are usually restricted to research settings and carry less weight  
700 in the upgrade of variants. Our study also demonstrates that proteomics can be delivered  
701 alongside ultra-rapid genomic sequencing approaches to provide functional data in a  
702 clinically relevant timeline.

703

## 704 **Materials and Methods**

### 705 *Ethics statement*

706 This study was conducted in accordance with the revised Declaration of Helsinki and  
707 following the Australian National Health and Medical Research Council statement of  
708 ethical conduct in research involving humans. Samples were obtained after receiving  
709 written, informed consent for diagnostic or research investigations from the respective  
710 responsible human ethics institutional review boards. HREC/RCH/34228,  
711 HREC/RCH/34183, HREC/89419/RCHM-2022 and HREC/82160/RCHM-2022 were

712 approved by the Royal Children's Hospital, Melbourne, Ethics in Human Research  
713 Committee. HREC/16/MH/251 was approved by the Melbourne Hospital Ethics in Human  
714 Research Committee. The REC reference 2002/205 by the Newcastle and North  
715 Tyneside Local Research Ethics Committee.

716

#### 717 *Genomic investigations*

718 Genomic investigations resulting in diagnosis of patients within the validation cohort (VC)  
719 are described in the publications indicated by PMID within **Supplementary Table 1**, with  
720 the exceptions of VC13 (*SDHAF1*), VC15 (*UQCRC2*) and VC24 (*FARS2*) which are as  
721 follows; Individual VC13 (*SDHAF1*) underwent clinical singleton WES through Baylor  
722 Genetics as previously described<sup>74</sup>. For individual VC15 (*UQCRC2*), homozygosity  
723 mapping from Illumina HumanCytoSNP-12 v2.1 array data identified substantial long  
724 contiguous stretches of homozygosity (LCSH) accounting for ~3.7% of the genome. Due  
725 to the observed complex III RCE defect in this patient, candidate gene sequencing of  
726 exons using genomic DNA through PCR and sanger sequencing was performed on  
727 complex III-related genes *UQCC1* and *UQCRC2* which lay within these regions of LCSH  
728 (primers available upon request). Blood DNA for individual VC24 (*FARS2*) underwent  
729 clinical singleton WES testing through the Victorian Clinical Genetics Service (VCGS) as  
730 previously described<sup>75</sup>. mtDNAseq was also used to quantify mtDNA variant  
731 heteroplasmy levels for individuals VC6 (*MT-ND1*) and VC12 (*MT-ND5*) as previously  
732 described<sup>75</sup>. Individuals within the undiagnosed patient (UDP) cohort were investigated  
733 as follow: blood DNA from UDP1 (*MT-ATP6*) underwent WES with mitochondrial DNA  
734 sequencing (mtDNAseq) as part of the Australian Genomics Mitochondrial Flagship as  
735 described<sup>75</sup>. For individual UDP4 (*CCDC47*), sequencing and analysis was performed as  
736 previously described<sup>25</sup>. Individual UDP5 (*NDUFA10*) had the Comprehensive Metabolism  
737 Panel performed by Blueprint Genetics. Individuals UDP6 (*NDUFA13*) and UDP7  
738 (*NDUFAF6*) both underwent clinical trio WES through the Victorian Clinical Genetics  
739 Service (VCGS)<sup>75</sup>. UDP8 (*NDUFS8*) had acute-care rapid trio WGS and analysis at the  
740 VCGS as previously published<sup>65</sup>.

741

#### 742 *Respiratory chain enzymology*

743 Respiratory chain enzyme activities in fibroblasts and skeletal muscle were measured by  
744 spectrophotometry as described<sup>10</sup>. Complex I (CI) was measured as rotenone-sensitive  
745 NADH:coenzyme Q<sub>1</sub> oxidoreductase, Complex II (CII) as succinate:coenzyme Q<sub>1</sub>  
746 oxidoreductase, Complex III (CIII) as decylbenzylquinol:cytochrome c reductase, and  
747 Complex IV (CIV) as cytochrome c oxidase. Citrate synthase (CS) was measured as



748 production of coenzyme A (CoA.SH) from oxaloacetate using the thiol reagent 5,5'-dithio-  
749 bis-(2-nitobenzoic acid). Enzyme activities were calculated as initial rates (CI, CII, and  
750 CS) or as first-order rate constants (CIII and CIV)<sup>10</sup>.

751

#### 752 *Cell Culture Conditions*

753 Fibroblast and HEK293T cell lines were cultured in Dulbecco's Modified Eagle Medium  
754 (DMEM) High Glucose, Sodium Pyruvate and Glutamine (Sigma-Aldrich) supplemented  
755 with 10% (v/v) Fetal Calf Serum (FCS; CellSera), 100 U/mL Penicillin-Streptomycin  
756 (Gibco) and 50 µg/mL Uridine. Cells were maintained at 37°C with 5% CO<sub>2</sub>.

757

#### 758 *Generation of knockout lines*

759 The NDUFS2<sup>KO</sup> cell line was generated using a CRISPR/Cas9 plasmid encoding the  
760 guide RNA 5'-TGAGGGCTTTGTGCGGCTTCCGG-3' cloned into the pSpCas9-2A-GFP  
761 vector<sup>26</sup>. The CRISPR was transfected into HEK293T cells and single cells were obtained  
762 by Fluorescence-activated cell sorting at the Monash Flow Cytometry Platform (Flowcore).  
763 Single cell populations were screened by loss of cell viability on galactose-containing  
764 DMEM and subsequently validated by the loss of protein by western blotting and indel  
765 sequencing, which identified two deletions c.[18\_36del] and c.[17\_42del] (Supplementary  
766 table 1). The UQCRC2<sup>KO</sup> cell line was generated using a CRISPR/Cas9 plasmid encoding  
767 the guide RNA 5'-CACCGGTACTIONACATCACCCCGC designed using the  
768 CHOPCHOP tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously  
769 described<sup>26</sup>. The plasmids were validated by sequencing, and then transfected into target  
770 cell lines using Lipofectamine™ 3000 Transfection Reagent (Thermo Fischer Scientific)  
771 according to manufacturer's guidelines. Single cells expressing GFP were isolated on a  
772 FACS Aria Fusion (BD Biosciences) cell sorter and clonal populations were subsequently  
773 screened for relevant gene knockouts using SDS-PAGE and immunoblotting and indel  
774 sequencing, which identified two deletions c.[9141\_9199del] and [9146\_9167del]  
775 (Supplementary table 1). The SURF1<sup>KO</sup> cell line was generated using a CRISPR/Cas9  
776 system with the HEK293T parental cell line. Two guide RNAs targeting the 5'UTR and  
777 exon 2 regions of *SURF1* were cloned into individual pSpCas9-2A-GFP vectors (Addgene,  
778 plasmid 48138<sup>18</sup>). Both constructs were transfected simultaneously into HEK293T cells  
779 using Lipofectamine 3000 (Thermo Fisher Scientific), according to the manufacturer's  
780 instructions. Verification of successful HEK293T SURF1<sup>KO</sup> was performed via three  
781 primer screening PCR were used to amplify incorporated indels via PCR and by SDS-  
782 PAGE immunoblotting. The product of external Primers (outside the double CRISPR  
783 target sites) underwent M13 primer Sanger Sequencing of alleles, using the Topo™ TA

784 Cloning Kit (Thermo Fisher Scientific) as per the manufacturer's instructions. Sequencing  
785 identified two deletions [c.18\_219del] and [c.18\_221delinCG] (Supplementary table 1).  
786 The ATP5PD<sup>KO</sup> cell line was generated using a CRISPR/Cas9 plasmid encoding the  
787 guide RNA 5'-CACCGCCTTTCCTTGTGGGCAGGT designed using the CHOPCHOP  
788 tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously described<sup>26</sup>. The  
789 plasmids were validated by sequencing, and then transfected into target cell lines using  
790 Lipofectamine™ 3000 Transfection Reagent (Thermo Fischer Scientific) according to  
791 manufacturer's guidelines. Single cells expressing GFP were isolated on a FACS Aria  
792 Fusion (BD Biosciences) cell sorter and clonal populations were subsequently screened  
793 for relevant gene knockouts using indel sequencing, which identified a single deletion  
794 c.[33481insT] (Supplementary table 1).

795

#### 796 *PBMC isolation from whole blood*

797 Neonatal blood samples were collected from healthy neonates following routine  
798 intramuscular administration of Vitamin K. For older infants and children ages 30 days to  
799 18 years, venous blood samples were obtained from hospital outpatients undergoing  
800 minor elective day surgery. An outline of the study protocol and complete detail of  
801 participant recruitment, inclusion and exclusion criteria and sample collection are  
802 described in our previously published HAPPI Kids study protocol<sup>76</sup>. PBMCs were isolated  
803 from fresh blood samples of the 37 HAPPI Kids controls using Ficoll®-Paque Plus (GE  
804 Healthcare Life Sciences) according to the instructions of the manufacturer with manual  
805 removal of the PBMC layer using a Pasteur pipette. For the UDP6 (*NDUFA13*), UDP7  
806 (*NDUFAF6*) and UDP8 (*NDUFS8*) probands, PBMC isolation using Ficoll®-Paque Plus  
807 was performed in SepMate™ tubes (STEMCELL Technologies), based on  
808 manufacturer's protocols with moderate braking applied for both washes, and a reduction  
809 in centrifugation speed and duration to 200 g for five minutes for the second wash.

810

#### 811 *Data-Independent Acquisition Mass Spectrometry of Fibroblast, HEK293T and PBMCs* 812 *Cohorts and Data Analysis*

813

#### 814 *Spectral Library Sample Preparation*

815 A HEK293T spectral library was generated from both whole cell and mitochondrial  
816 HEK293T samples to search data-independent acquisition (DIA) HEK293T knockout cell  
817 lines. A total of 100 µg of mitochondrial sample isolated from wildtype HEK293T cells  
818 underwent carbonate extraction at pH 11.5 to separate soluble and integral mitochondrial  
819 proteins, as previously described<sup>77</sup>. The resulting pellet and supernatant samples, as well

820 as 25 µg whole cell HEK293T sample, were solubilized in lysis buffer for a final  
821 composition of 5% SDS and 50 mM Triethylammonium bicarbonate (TEAB) pH 8.5. The  
822 lysed whole cell, mitochondrial pellet and supernatant samples were processed using S-  
823 trap™ Micro Spin Columns (ProtiFi) according to the manufacturer's instructions, where  
824 samples were reduced with 40 mM 2-chloroacetamide (CAA, Sigma) and alkylated with  
825 10 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; BondBreaker, Thermo  
826 Fischer Scientific). Isolated proteins were digested at 1:25 trypsin to protein ratio at 37°C  
827 overnight and eluted peptides were dried down using a CentriVap Benchtop Vacuum  
828 Concentrator (Labconco). Fibroblasts and PBMCs spectral libraries were generating from  
829 whole cell samples of either five healthy fibroblast controls or PBMC pellets isolated from  
830 39 healthy individuals ranging from 0-17 years old. Fibroblast or PBMC pellets were  
831 solubilized 5% SDS and 50 mM TEAB pH 8.5, and total protein determined by Pierce  
832 bicinchoninic acid (BCA) Protein Assay Kit (Thermo Fisher Scientific). A total of 25 µg for  
833 each control was processed using the S-Trap™ Micro Spin Columns (ProtiFi), as  
834 described above.

835 Peptides from HEK293T, fibroblast and PBMC samples were reconstituted in 0.5% formic  
836 acid (FA) for fractionation. Fibroblast and PBMC control samples were pooled upon  
837 reconstitution to create a single fibroblast, HEK293T and PBMC peptide mixture and  
838 loaded onto a strong cation exchange (Empore Cation Exchange-SR, Supelco Analytical)  
839 stage-tips made as described<sup>78</sup>. Stage tips were washed with 20% acetonitrile (ACN) and  
840 0.5% FA and eluted over seven fractions of increasing concentrations of ammonium  
841 acetate (45-300 mM), 20% ACN and 0.5% FA for whole cell fibroblasts, PBMC and  
842 HEK293T samples. HEK293T mitochondrial and supernatant samples, were collected  
843 over five fractions. All samples underwent a final elution with 5% ammonium hydroxide  
844 and 80% ACN, followed by concentration using a CentriVap Benchtop Vacuum  
845 Concentrator (Labconco). Fractions were desalted on SDB-XC (poly(styrene-divinyl-  
846 benzene); Supelco Analytical) stage tips made in-house as previously described<sup>78</sup>.

847

#### 848 *Spectral Library Mass Spectrometry Data Dependent Acquisition*

849 Fractions were reconstituted in 0.1% trifluoroacetic acid (TFA) and 2% ACN and each  
850 library was analyzed by liquid chromatography (LC)-tandem mass spectrometry (MS/MS)  
851 on an Orbitrap Eclipse Mass Spectrometer (Thermo Fischer Scientific) operating on DDA  
852 mode over a 125-minute gradient. Tryptic peptides were loaded onto an Acclaim Pepmap  
853 nano-trap column (Dinoex-C18, 100 Å, 75 µm × 2 cm) at an isocratic flow of 5 µl/min of  
854 2% ACN and 0.1% FA for six minutes before switching with an Acclaim Pepmap RSLC  
855 analytical column (Dinoex-C18, 100 Å, 75 µm × 50 cm). The separation of peptides was

856 performing using a nonlinear 125-minute gradient of solvent A (5% dimethyl sulphoxide  
857 (DMSO), 0.1% FA) and solvent B (5% DMSO, 100% ACN, 0.1% FA). The flow gradient  
858 was (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-  
859 40% solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent  
860 B, (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes  
861 before the next injection. Briefly, the data was collected using positive polarity with a MS1  
862 scan range of 375-1500 m/z and resolution set to 120,000. Other MS1 instrument  
863 parameters include: ACG target of 4e5, maximum injection time of 50 ms and Isolation  
864 window of 1.6. MS2 instrument parameters include: scan range of 150-2000 m/z,  
865 resolution of 15,000, HCD collision energy of 30%, ACG target of 5e3, maximum injection  
866 time of 22 ns and dynamic exclusion of 30 s.

867

#### 868 *Sample Preparation of HEK293T, PBMC and Fibroblast Cell Lines*

869 Whole cell pellets of HEK293T cells, PBMCs and fibroblasts were collected and washed  
870 twice with PBS before resuspension in 5% SDS, 50 mM tetraethylammonium bromide  
871 (TEAB) pH 8.5 buffer and 125 U of benzonase per ml (Sigma-Aldrich). Skeletal muscle  
872 samples were solubilized with a probe sonicator with 30% amplitude in 5% SDS, 50 mM  
873 TEAB pH 8.5 buffer on ice with a cycle of 10 seconds on 10 seconds off for 1 minute and  
874 clarified at 16,000 x g for 5 minutes. Protein concentration was performed with Pierce  
875 BCA Protein Assay Kit (Thermo Fisher Scientific) and 25 µg of each sample was aliquoted  
876 in triplicates for patients and singlicate for individual controls (N=3-5). Samples were  
877 processed using S-trap™ micro spin columns (ProtiFi) according to the manufacturer's  
878 instructions. Proteins were digested with trypsin (Thermo Fisher Scientific) at 1:10 trypsin  
879 to protein ratio. Peptides were dried down using a CentriVap Benchtop Vacuum  
880 Concentrator (Labconco) and reconstituted in 45 µL 2% ACN, 0.1% trifluoroacetic acid  
881 (TFA) and 2 µL injected for liquid chromatography tandem mass spectrometry (LC-  
882 MS/MS). Samples were analyzed for 125 minutes (HEK293T) or 95 minutes (Fibroblasts,  
883 skeletal muscle, PBMCs) on an Orbitrap Eclipse mass spectrometer (Thermo Fisher  
884 Scientific) operating in DIA mode.

885

#### 886 *Mass Spectrometry Data Independent Acquisition*

887 Peptides were reconstituted in 45 µL of 2% ACN and 0.1% TFA and 2 µl was injected into  
888 an Orbitrap Eclipse mass spectrometer (Thermo Fischer Scientific) for LC-MS/MS  
889 analysis equipped with trap and analytical columns described above. All samples were  
890 analysed with the mass spectrometer operating in DIA mode. The separation of peptides  
891 was performed using a nonlinear gradient of solvent A and solvent B across 125-minutes

892 for HEK293T knockout cell lines, and 95-minutes for all other sample types (fibroblasts,  
893 PBMCs and skeletal muscle). Briefly, for the 125-minute method, the flow gradient was  
894 (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-40%  
895 solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent B,  
896 (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes  
897 before the next injection. The data was collected using positive polarity with a MS1 scan  
898 range of 350-1200 m/z at a resolution of 120,000. Other MS1 instrument parameters  
899 include: ACG target of 1e6, maximum injection time of 50 ms, Isolation window of 24 with  
900 1 m/z overlap. For MS2 parameters, the scan range was 200-2000 m/z at 15,000  
901 resolution, HCD collision energy of 30%, AGC target of 1e6 and maximum injection time  
902 of 22 ms. For the 95-minute method, the flow gradient was (i) 0-6 min at 3% solvent B,  
903 (ii) 6-7 min at 3-4% solvent B, (iii) 7-82 min at 4-25% solvent B, (iv) 82-86 min at 25-40%  
904 solvent B, (v) 86-87 min at 40-80% solvent B, (vi) 87-90 min at 80-80% solvent B, (vii) 90-  
905 91 min at 80-3% solvent B and equilibrated at 3% solvent B for 5 minutes before the next  
906 injection. Instrument parameters were consistent with those used in the 125-minute  
907 method described above, with changes made to the following parameters: MS1 scan  
908 range of 350-1400 m/z, MS1 maximum injection time of 45 ms, Isolation window of 13.7  
909 and MS2 ACG target of 5e5.

910

#### 911 *Proteomic data search*

912 For spectral library, raw files were imported into Spectronaut<sup>®79</sup> (v.15.2.210819.50606 for  
913 HEK293T library, v.14.8.201029.4778 for fibroblasts library, v. 16.0.220606.53000 for  
914 PBMCs library) and the three libraries were generated using the 'Pulsar' option with  
915 default BGS Factory settings, searching against Uniprot human database containing  
916 reviewed canonical and isoforms sequences (42,386 entries). The resulting HEK293T  
917 library contained 194,270 precursors, the fibroblast library contained 131,627 precursors,  
918 and the PBMC library contained 148,522 precursors. For DIA samples, raw files were  
919 imported into Spectronaut<sup>®</sup> and searched against the libraries generated above. Default  
920 BGS Factory search parameters were used with changes made to exclude single hit  
921 proteins, no selection of 'Major Group Top N' and 'Minor Group Top N' and data filtering  
922 setting set to 'Q-value' or 'Q-value sparse' with 'run-wise imputation' as an imputing  
923 strategy. 'Q-value' datasets (unimputed) were used for generation of RCA values while  
924 'Q-value sparse' with 'run-wise imputation' datasets were used to generate heatmaps and  
925 correlation plots to reduce missing values for visualization, and in volcano plots for VC  
926 and KC cohorts or when the protein of interest was not well detected. UDP1 (*MT-ATP6*)  
927 data was also searched using BGS Factory direct DIA settings (library free) with changes



928 as above with inclusion of the p.Met228 variant peptide fasta file in the protein database  
929 search. SC1 and SC2 (*TMEM70*) skeletal muscle were searched with default BGS  
930 Factory direct DIA settings with changes as above.

931  
932 *Protein filtering and clean up*  
933 Proteins were filtered in each cohort to ensure that the data was of high quality and with  
934 a minimal amount of missing data for analysis. Proteins within the validation cohort (VC)  
935 were filtered out if identified by a single peptide in all controls or proband samples,  
936 maintaining proteins that were identified by >2 peptides in both groups. Proteins were  
937 then filtered to least three or more valid values for the controls and at least two or more  
938 valid values for the proband samples. For the knockout cohort (KC), proteins were filtered  
939 out if identified by a single peptide in all controls and proband samples. Proteins were  
940 then filtered to at least two valid values for the controls and at least two valid values for  
941 the knockout sample. For the undiagnosed proband cohort (UDP), proteins were filtered  
942 out if identified by a single peptide in all controls or proband samples. Proteins were then  
943 filtered for 70% valid values for the controls due to the different number of controls per  
944 batch and 70% valid values for the proband samples. For the supporting cohort (SC),  
945 samples SC1, SC2, SC3 and SC5 proteins were filtered out if identified by a single peptide  
946 in all controls or proband samples. Proteins were then filtered for 70% valid values for the  
947 controls and 70% valid values for the proband samples. Sample SC4 had no filtering  
948 completed as this was a previously published dataset<sup>21</sup> and the data was unlogged and  
949 complex subunit gene names manually updated to match the current MitoCarta3.0  
950 naming convention for Complex V subunits. For the 36 PBMC control samples (SC6-41),  
951 proteins were filtered out if they were identified by a single peptide across all 36 samples  
952 and further filtered for at least 70% valid values.

953  
954 *Relative Complex Abundance Plots*  
955 Relative complex abundance (RCA) plots were generated for all VC, KC, SC and UDP  
956 cohorts and plots can be viewed within the RDMS Explorer platform. All samples  
957 underwent mitochondrial normalization where the mean of the mitochondrial proteins for  
958 each specific sample was determined using the average of all control mitochondrial  
959 proteins or proband mitochondrial proteins and then used as a normalization factor for  
960 each group and applied to each sample. To develop the RCA plots, the average of the  
961 proband and controls was determined and then transformed to log<sub>10</sub>. The difference  
962 between the log<sub>10</sub> of the proband and controls was determined and then unlogged.  
963 Statistical difference between the control and proband complex subunits was determined



964 using a paired t-test and summary statistics including mean and the error bars indicating  
965 standard deviation were determined for each complex and the graph plotted within R  
966 (v.4.3.2). Complex subunits were determined using curated annotations from  
967 MitoCarta3.0<sup>28</sup>. For Supplementary Fig. A, relative mitochondrial abundance from  
968 MitoCarta3.0 '+' entries were generated as above without the mitochondrial normalization  
969 step. For Supplementary Fig. B, control mitochondrial abundance plots were generated  
970 using log<sub>2</sub> abundances from MitoCarta3.0 '+' entries for each batch and significance  
971 performed with an ANOVA test.

972

### 973 *Protein range graphs*

974 Protein range graphs were developed using an in-house R script. The median of the  
975 protein of interest in control samples is calculated as well as the median of the proband  
976 replicates. The log<sub>2</sub> fold-change is calculated between the proband and control and  
977 converted to percentage for the proband as the abundance relative to the control median  
978 for plotting. The range of the controls is also displayed as the abundance relative to the  
979 control median. The log<sub>2</sub> abundance per standard deviation (SD) is rounded to one  
980 decimal place with the top axis SD present to determine how many standard deviations  
981 the protein is from the control median.

982

### 983 *Volcano and Correlation plots*

984 The peptide and valid value cleaned matrices for all samples were annotated with  
985 MitoCarta3.0<sup>28</sup> entries in Perseus<sup>80</sup>. All analyses were performed in Perseus v 1.6.14.0.  
986 Volcano plots were visualized using scatter plot function from a two-sample t-test using  
987 p-value threshold of 0.05 in Perseus. For the correlation plots (Fig 3B, Supplementary  
988 Fig.2B), proteomic data searched with q-value sparse with run-wise imputation settings  
989 were correlated via gene name using gene name entries and the logFCs in R and plotted  
990 using scatter plot function in Perseus. For Fig. 4C, previously published data from  
991 MRPL50 Fibroblasts<sup>21</sup> were correlated with MRPL50 PBMCs using gene name entries  
992 and the logFCs in R and plotted using scatter plot function in Perseus.

993

### 994 *RDMS Explorer Website.*

995 All the code used to develop the RDMS Explorer website  
996 (<https://rdmassspec.shinyapps.io/RDMSExplorer/>) and in-house analysis performed in R  
997 can be found at (<https://doi.org/10.5281/zenodo.12883602>) and  
998 ([https://github.com/njcaruana/rdms\\_oxphos](https://github.com/njcaruana/rdms_oxphos)).

999

1000 *Heatmaps and Venn diagrams*

1001 For heatmaps output matrices searched with q-value sparse run-wise imputation settings  
1002 Spectronaut runs were log<sub>2</sub> transformed and a two-sided t-test using p-value for  
1003 truncation was performed in Perseus for each cell line against their respective batch  
1004 controls. The Morpheus software was used for heatmap visualization  
1005 (<https://software.broadinstitute.org/morpheus>). For Supplementary Fig. 1A, proteins were  
1006 manually annotated based on MitoCarta3.0 as 'assembly factor' or 'complex I-V' and  
1007 subset for visualization in Morpheus using the following parameters metric 'one minus  
1008 Pearson correlation', linkage method 'average', cluster 'rows' and group columns by  
1009 'complex/assembly factor'. P-value results from t-test statistical analysis were used to  
1010 visualize the significance of each data point by overlaying the p-value matrix onto the t-  
1011 test matrix in Morpheus and using the option size by 'p-value matrix' size minimum '0'  
1012 and maximum '1.301' (p-value<0.05). For the correlation heatmap plot (Supplementary  
1013 Fig. 2A), hierarchical clustering was used with the following parameters in Morpheus:  
1014 metric 'one minus Pearson correlation', linkage method 'average' and cluster 'columns'.  
1015 Topographical heatmaps (Supplementary Fig. 1B) were generated from log<sub>2</sub>-transformed  
1016 fold-change from t-test in Pymol using the PDB structures (CI: 5LDW, CII: 1ZOY, CIII:  
1017 1BGY, CIV: 5Z62, CV: 7AJD) as previously described<sup>26</sup>. Venn diagrams were generated  
1018 with DeepVenn<sup>81</sup> from gene names. Green (diagnostic-grade) and amber (borderline  
1019 diagnostic-grade) lists for mitochondrial disease (v.0.787) and Mendeliome gene lists  
1020 (v.0.12869) were retrieved from PanelApp Australia<sup>27</sup>.

1021

1022 *Principal Component Analysis and Donut plots*

1023 PCA plots were generated in Perseus v 1.6.14.0 from t-test fold-change data for VC  
1024 cohort (Fig. 1B) or protein abundances for PBMCs controls (Fig. 4B). Donut plots were  
1025 generated in GraphPad Prism (v.10.2.0).

1026

1027 *RNA sequencing and transcriptomic analysis*

1028 RNA sequencing and analysis was performed as described<sup>20</sup>. In brief, RNA was extracted  
1029 from muscle using miRNeasy Mini Kit (Qiagen) and treated with RNase-Free DNase  
1030 (Qiagen) and RNA quality and quantity measured using TapeStation RNA ScreenTape  
1031 analysis (Agilent) and Qubit RNA HS (Thermo Fisher Scientific). UDP4 underwent  
1032 RNAseq within a group of 10 undiagnosed patients with available muscle samples, all  
1033 with an RNA integrity number of 7.2 - 8.9. The Kapa Biosystems mRNA Hyper Prep Kit  
1034 was used to generate sequencing libraries from 500ng RNA, and paired-end sequencing

1035 on an Illumina instrument was performed at the Yale Center of Genome Analysis to  
1036 achieve 50-100 million read coverage.

1037  
1038 For outlier detection, 100 control muscle samples were retrieved from GTEx using the  
1039 Sequence Read Archive (SRA) toolkit and converted into FASTQ using Fastq-dump.  
1040 Patient and control FASTQ files were aligned to hg38 human reference genome with  
1041 GENCODE v26 annotations using STAR (v2.5.3a), with twopassMode = 'Basic' to enable  
1042 detection of novel splice junctions, and duplicates marked using Picard (v2.9). RNA-  
1043 SeQC (v2.3.4) was used to generate quality metrics from STAR-aligned bam files.  
1044 Outliers were removed per the following criteria: (a) <45 million QC-passed reads, (b)  
1045 <18,000 genes detected and (c) manual identification via Principal Component Analysis.  
1046 This resulted in the removal of 11 samples, leaving 89 control samples from muscle.  
1047 Outlier expression was assessed using the DROP (Detection of RNA Outliers Pipeline)  
1048 pipeline v0.9.0 (<https://github.com/gagneurlab/drop>), with default settings<sup>82</sup>. Analysis was  
1049 restricted to 6106 genes, which included Mendeliome and 'MitoExome' genes, as  
1050 described previously<sup>20</sup>.

1051  
1052 *cDNA studies*

1053 The total RNA extracted from skeletal muscle for RNA sequencing was also synthesized  
1054 into cDNA using the SuperScript III First-Strand Synthesis System (Thermo Fisher  
1055 Scientific) as per both manufacturer's protocols and as described previously<sup>83</sup>. To  
1056 examine mRNA splicing in *CCDC47*, PCR primers (5' GCGTGACTGAGCTACGGTT 3';  
1057 5' CTCTGGGATGGCTTTACATGG 3') were designed to amplify the entire ORF from  
1058 cDNA. PCR products were analyzed on 1% agarose (Bioline) gels using a 1-kb Plus DNA  
1059 Ladder (Thermo Fisher Scientific) prior to cloning into a pCR2.1-TOPO vector using the  
1060 TOPO TA cloning kit (Thermo Fisher Scientific) and transformation into TOP10 competent  
1061 cells (Thermo Fisher Scientific). Individual colonies were examined and then underwent  
1062 sanger sequencing.

1063  
1064 **Conflict of Interest**

1065 The authors declare that the research was conducted in the absence of any commercial  
1066 or financial relationships that could be construed as a potential conflict of interest.

1067  
1068 **MitoMDT Diagnostic Network for Genomics and Omics**

1069 David R Thorburn, Aleksandra Filipovska, Michael T Ryan, David A Stroud, Diana  
1070 Stojanovski, David Coman, Sean Murray, Ryan L Davis, John Christodoulou, Roula

1071 Ghaoui, Suzanne CEH Sallevelt, Cas Simons, Stefan J Siira, Shanti Balasubramaniam,  
1072 Alison G Compton, Daniel G MacArthur, Nicole J Lake, Amanda Samarasinghe, Yoni  
1073 Elbaum, Catherine Atthow, Pauline McGrath, Ellenore M Martin, Madeleine Harris, Tegan  
1074 Stait, Leah E Frajman, Simone Tregoning

1075

#### 1076 **Author contribution**

1077 Conceptualization: DHH, DRT, DAS

1078 Methodology: DHH, NJC, LNS, NJL, LuEF, SSCA, TS, ST, LeEF, DRLR, MB, BoR, AGC,  
1079 VK, CA

1080 Investigation: DHH, MB, BrR, MJW, AV, CB, HP, JL, ZS, RM, RWT, AGC, WB, NBT, MLF

1081 Visualization: DHH, NJC, LNS, NJL, SSCA

1082 Website design and coding: NJC

1083 Funding acquisition: DHH, JC, AGC, DRT, DAS

1084 Project administration: AS, RB, DRT, DAS

1085 Supervision: PM, ML, RM, RWT, MTR, ZS, JC, AGC, DRT, DAS

1086 Writing – original draft: DHH, DRT, DAS

1087 Writing – review & editing: all authors reviewed and edited the manuscript

1088

#### 1089 **Funding**

1090 This research was supported by Australian National Health and Medical Research  
1091 Council (NHMRC) Project and Ideas grants (1140906 to DAS; 1164479 to DRT; 2010939  
1092 to MTR), Investigator Fellowships (2009732 to DAS, 2010149 to LuEF and 1155244 to  
1093 DRT) and a Principal Research Fellowship (1155244 to DRT) along with funding by  
1094 Australian Genomics Health Alliance (Australian Genomics) NHMRC Targeted Call for  
1095 Research grant GNT1113531. Additional support came from the Australian Medical  
1096 Research Future Fund Genomics Health Futures Mission (2007959 to DRT) and Acute  
1097 Care Genomics (GHFM76747). The US Department of Defense Congressionally Directed  
1098 Medical Research Programs (PR170396 to DRT). We thank the Mito Foundation for the  
1099 provision of instrumentation through research equipment grants to DAS and DHH.  
1100 Additionally, LuEF acknowledges support from the Mito Foundation. This work was also  
1101 supported by grants from Royal Children’s Hospital Foundation [2021-1377]. Work at the  
1102 MCRI is supported through the Victorian Government’s Operational Infrastructure  
1103 Support Program. RWT is funded by the Wellcome Centre for Mitochondrial Research  
1104 (203105/Z/16/Z), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Medical  
1105 Research Council (MR/W019027/1), the Lily Foundation, Mito Foundation, the  
1106 Pathological Society, the UK NIHR Biomedical Research Centre for Ageing and Age-  
1107 related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust,

1108 LifeArc and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of  
1109 Adults and Children.

1110

### 1111 **Acknowledgments**

1112 We acknowledge and thank all the families who contributed to this study. We thank all  
1113 members of the Stroud and Stojanovski lab for input into experimental design and  
1114 interpretation of data. We thank the Bio21 Mass Spectrometry and Proteomics Facility  
1115 (MMSPF) for the provision of instrumentation, training, and technical support. The Chair  
1116 in Genomic Medicine awarded to JC is generously supported by The Royal Children's  
1117 Hospital Foundation. The authors thank staff of the Pathology Collection Department at  
1118 The Royal Children's Hospital for obtaining the consent of participants and the collection  
1119 of samples. The authors thank staff of the Anaesthetic and Surgical Departments at the  
1120 Royal Children's Hospital.

1121

### 1122 **Data Availability Statement**

1123 The mass spectrometry proteomics data have been deposited to the ProteomeXchange  
1124 Consortium via the PRIDE<sup>84</sup> partner repository with the dataset identifier PXD055473.  
1125 De-identified genomic data from this study are available for ethically approved research.  
1126 For queries about the genomic data sets please contact: david.thorburn@mcri.edu.au.

1127

### 1128 **References**

- 1129 1. Haack, T.B. *et al.* Molecular diagnosis in mitochondrial complex I deficiency using  
1130 exome sequencing. *J Med Genet* **49**, 277-283 (2012).
- 1131 2. Taylor, R.W. *et al.* Use of whole-exome sequencing to determine the genetic basis of  
1132 multiple mitochondrial respiratory chain complex deficiencies. *JAMA* **312**, 68-77  
1133 (2014).
- 1134 3. Ohtake, A. *et al.* Diagnosis and molecular basis of mitochondrial respiratory chain  
1135 disorders: exome sequencing for disease gene identification. *Biochim Biophys Acta*  
1136 **1840**, 1355-1359 (2014).
- 1137 4. Wortmann, S.B., Koolen, D.A., Smeitink, J.A., van den Heuvel, L. & Rodenburg, R.J.  
1138 Whole exome sequencing of suspected mitochondrial patients in clinical practice. *J*  
1139 *Inherit Metab Dis* **38**, 437-443 (2015).
- 1140 5. Davis, R.L. *et al.* Use of Whole-Genome Sequencing for Mitochondrial Disease  
1141 Diagnosis. *Neurology* **99**, e730-e742 (2022).
- 1142 6. Frazier, A.E., Thorburn, D.R. & Compton, A.G. Mitochondrial energy generation  
1143 disorders: genes, mechanisms, and clues to pathology. *J Biol Chem* **294**, 5386-5395  
1144 (2019).
- 1145 7. Gorman, G.S. *et al.* Mitochondrial diseases. *Nat Rev Dis Primers* **2**, 16080 (2016).
- 1146 8. Skladal, D., Halliday, J. & Thorburn, D.R. Minimum birth prevalence of mitochondrial  
1147 respiratory chain disorders in children. *Brain* **126**, 1905-1912 (2003).
- 1148 9. Smeets, H.J.M., Sallevelt, S. & Herbert, M. Reproductive options in mitochondrial  
1149 disease. *Handb Clin Neurol* **194**, 207-228 (2023).



- 1150 10. Frazier, A.E., Vincent, A.E., Turnbull, D.M., Thorburn, D.R. & Taylor, R.W.  
1151 Assessment of mitochondrial respiratory chain enzymes in cells and tissues.  
1152 *Methods Cell Biol* **155**, 121-156 (2020).
- 1153 11. Kremer, L.S. *et al.* Genetic diagnosis of Mendelian disorders via RNA sequencing.  
1154 *Nat Commun* **8**, 15824 (2017).
- 1155 12. Yepez, V.A. *et al.* Clinical implementation of RNA sequencing for Mendelian disease  
1156 diagnostics. *Genome Med* **14**, 38 (2022).
- 1157 13. Fresard, L. *et al.* Identification of rare-disease genes using blood transcriptome  
1158 sequencing and large control cohorts. *Nat Med* **25**, 911-919 (2019).
- 1159 14. Murdock, D.R. *et al.* Transcriptome-directed analysis for Mendelian disease  
1160 diagnosis overcomes limitations of conventional genomic testing. *J Clin Invest* **131**  
1161 (2021).
- 1162 15. Chen, E. *et al.* Rates and Classification of Variants of Uncertain Significance in  
1163 Hereditary Disease Genetic Testing. *JAMA Netw Open* **6**, e2339571 (2023).
- 1164 16. Alston, C.L., Stenton, S.L., Hudson, G., Prokisch, H. & Taylor, R.W. The genetics of  
1165 mitochondrial disease: dissecting mitochondrial pathology using multi-omic  
1166 pipelines. *J Pathol* **254**, 430-442 (2021).
- 1167 17. Kopajtich, R. *et al.* Integration of proteomics with genomics and transcriptomics  
1168 increases the diagnostic rate of Mendelian disorders. *medRxiv*,  
1169 2021.2003.2009.21253187 (2021).
- 1170 18. Xiao, Q. & Lauschke, V.M. The prevalence, genetic complexity and population-  
1171 specific founder effects of human autosomal recessive disorders. *NPJ Genom Med*  
1172 **6**, 41 (2021).
- 1173 19. Sahni, N. *et al.* Widespread macromolecular interaction perturbations in human  
1174 genetic disorders. *Cell* **161**, 647-660 (2015).
- 1175 20. Amarasekera, S.S.C. *et al.* Multi-omics identifies large mitoribosomal subunit  
1176 instability caused by pathogenic MRPL39 variants as a cause of pediatric onset  
1177 mitochondrial disease. *Hum Mol Genet* **32**, 2441-2454 (2023).
- 1178 21. Bakhshalizadeh, S. *et al.* Deficiency of the mitochondrial ribosomal subunit,  
1179 MRPL50, causes autosomal recessive syndromic premature ovarian insufficiency.  
1180 *Hum Genet* **142**, 879-907 (2023).
- 1181 22. Helman, G. *et al.* Multiomic analysis elucidates Complex I deficiency caused by a  
1182 deep intronic variant in NDUFB10. *Hum Mutat* **42**, 19-24 (2021).
- 1183 23. Horvath, R. *et al.* Childhood onset mitochondrial myopathy and lactic acidosis  
1184 caused by a stop mutation in the mitochondrial cytochrome c oxidase III gene. *J*  
1185 *Med Genet* **39**, 812-816 (2002).
- 1186 24. Van Haute, L. *et al.* TEFM variants impair mitochondrial transcription causing  
1187 childhood-onset neurological disease. *Nat Commun* **14**, 1009 (2023).
- 1188 25. Lake, N.J. *et al.* Biallelic Mutations in MRPS34 Lead to Instability of the Small  
1189 Mitoribosomal Subunit and Leigh Syndrome. *Am J Hum Genet* **101**, 239-254 (2017).
- 1190 26. Stroud, D.A. *et al.* Accessory subunits are integral for assembly and function of  
1191 human mitochondrial complex I. *Nature* **538**, 123-126 (2016).
- 1192 27. Martin, A.R. *et al.* PanelApp crowdsources expert knowledge to establish  
1193 consensus diagnostic gene panels. *Nat Genet* **51**, 1560-1565 (2019).



- 1194 28. Rath, S. *et al.* MitoCarta3.0: an updated mitochondrial proteome now with sub-  
1195 organelle localization and pathway annotations. *Nucleic Acids Res* **49**, D1541-  
1196 D1547 (2021).
- 1197 29. Granata, C. *et al.* High-intensity training induces non-stoichiometric changes in the  
1198 mitochondrial proteome of human skeletal muscle without reorganisation of  
1199 respiratory chain content. *Nat Commun* **12**, 7056 (2021).
- 1200 30. Thompson, K., Stroud, D.A., Thorburn, D.R. & Taylor, R.W. Investigation of oxidative  
1201 phosphorylation activity and complex composition in mitochondrial disease. *Handb*  
1202 *Clin Neurol* **194**, 127-139 (2023).
- 1203 31. Bernier, F.P. *et al.* Diagnostic criteria for respiratory chain disorders in adults and  
1204 children. *Neurology* **59**, 1406-1411 (2002).
- 1205 32. Acin-Perez, R. *et al.* Respiratory complex III is required to maintain complex I in  
1206 mammalian mitochondria. *Mol Cell* **13**, 805-815 (2004).
- 1207 33. Rahman, S. *et al.* Leigh syndrome: clinical features and biochemical and DNA  
1208 abnormalities. *Ann Neurol* **39**, 343-351 (1996).
- 1209 34. Tucker, E.J. *et al.* Mutations in MTFMT underlie a human disorder of formylation  
1210 causing impaired mitochondrial translation. *Cell Metab* **14**, 428-434 (2011).
- 1211 35. Massa, V. *et al.* Severe infantile encephalomyopathy caused by a mutation in  
1212 COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. *Am J Hum Genet* **82**,  
1213 1281-1289 (2008).
- 1214 36. Hock, D.H., Robinson, D.R.L. & Stroud, D.A. Blackout in the powerhouse: clinical  
1215 phenotypes associated with defects in the assembly of OXPHOS complexes and  
1216 the mitoribosome. *Biochem J* **477**, 4085-4132 (2020).
- 1217 37. Zong, S. *et al.* Structure of the intact 14-subunit human cytochrome c oxidase. *Cell*  
1218 *Res* (2018).
- 1219 38. Signes, A. & Fernandez-Vizarra, E. Assembly of mammalian oxidative  
1220 phosphorylation complexes I-V and supercomplexes. *Essays Biochem* **62**, 255-270  
1221 (2018).
- 1222 39. Cizkova, A. *et al.* TMEM70 mutations cause isolated ATP synthase deficiency and  
1223 neonatal mitochondrial encephalocardiomyopathy. *Nat Genet* **40**, 1288-1290  
1224 (2008).
- 1225 40. Catteruccia, M. *et al.* Persistent pulmonary arterial hypertension in the newborn  
1226 (PPHN): a frequent manifestation of TMEM70 defective patients. *Mol Genet Metab*  
1227 **111**, 353-359 (2014).
- 1228 41. Torraco, A. *et al.* TMEM70: a mutational hot spot in nuclear ATP synthase deficiency  
1229 with a pivotal role in complex V biogenesis. *Neurogenetics* **13**, 375-386 (2012).
- 1230 42. Braczynski, A.K. *et al.* ATP synthase deficiency due to TMEM70 mutation leads to  
1231 ultrastructural mitochondrial degeneration and is amenable to treatment. *Biomed*  
1232 *Res Int* **2015**, 462592 (2015).
- 1233 43. Magner, M. *et al.* TMEM70 deficiency: long-term outcome of 48 patients. *J Inherit*  
1234 *Metab Dis* **38**, 417-426 (2015).
- 1235 44. Sanchez-Caballero, L. *et al.* TMEM70 functions in the assembly of complexes I and  
1236 V. *Biochim Biophys Acta Bioenerg* **1861**, 148202 (2020).

- 1237 45. Guerrero-Castillo, S. *et al.* The Assembly Pathway of Mitochondrial Respiratory  
1238 Chain Complex I. *Cell Metab* **25**, 128-139 (2017).
- 1239 46. Mowat, D. *et al.* Respiratory chain complex III [correction of complex] in deficiency  
1240 with pruritus: a novel vitamin responsive clinical feature. *J Pediatr* **134**, 352-354  
1241 (1999).
- 1242 47. Morimoto, M. *et al.* Bi-allelic CCDC47 Variants Cause a Disorder Characterized by  
1243 Woolly Hair, Liver Dysfunction, Dysmorphic Features, and Global Developmental  
1244 Delay. *Am J Hum Genet* **103**, 794-807 (2018).
- 1245 48. Yang, Q. *et al.* Clinical and genetic analysis of trichohepatoneurodevelopmental  
1246 syndrome caused by a CCDC47 variant. *Heliyon* **10**, e27955 (2024).
- 1247 49. Iannello, G. *et al.* Simple, Fast, and Efficient Method for Derivation of Dermal  
1248 Fibroblasts From Skin Biopsies. *Curr Protoc* **3**, e714 (2023).
- 1249 50. Amunts, A., Brown, A., Toots, J., Scheres, S.H.W. & Ramakrishnan, V. Ribosome.  
1250 The structure of the human mitochondrial ribosome. *Science* **348**, 95-98 (2015).
- 1251 51. Bakker, H.D. *et al.* Human alpha-N-acetylgalactosaminidase (alpha-NAGA)  
1252 deficiency: no association with neuroaxonal dystrophy? *Eur J Hum Genet* **9**, 91-96  
1253 (2001).
- 1254 52. Sung, A.Y. *et al.* Systematic analysis of NDUFAF6 in complex I assembly and  
1255 mitochondrial disease. *Nat Metab* **6**, 1128-1142 (2024).
- 1256 53. Pagliarini, D.J. *et al.* A mitochondrial protein compendium elucidates complex I  
1257 disease biology. *Cell* **134**, 112-123 (2008).
- 1258 54. McKenzie, M. *et al.* Mutations in the gene encoding C8orf38 block complex I  
1259 assembly by inhibiting production of the mitochondria-encoded subunit ND1. *J Mol*  
1260 *Biol* **414**, 413-426 (2011).
- 1261 55. Baide-Mairena, H. *et al.* Mutations in the mitochondrial complex I assembly factor  
1262 NDUFAF6 cause isolated bilateral striatal necrosis and progressive dystonia in  
1263 childhood. *Mol Genet Metab* **126**, 250-258 (2019).
- 1264 56. Hartmannova, H. *et al.* Acadian variant of Fanconi syndrome is caused by  
1265 mitochondrial respiratory chain complex I deficiency due to a non-coding mutation  
1266 in complex I assembly factor NDUFAF6. *Hum Mol Genet* **25**, 4062-4079 (2016).
- 1267 57. Kim, J., Lee, J. & Jang, D.H. NDUFAF6-Related Leigh Syndrome Caused by Rare  
1268 Pathogenic Variants: A Case Report and the Focused Review of Literature. *Front*  
1269 *Pediatr* **10**, 812408 (2022).
- 1270 58. Nguengang Wakap, S. *et al.* Estimating cumulative point prevalence of rare  
1271 diseases: analysis of the Orphanet database. *Eur J Hum Genet* **28**, 165-173 (2020).
- 1272 59. Van Bergen, N.J. *et al.* Severe NAD(P)HX Dehydratase (NAXD) Neurometabolic  
1273 Syndrome May Present in Adulthood after Mild Head Trauma. *Int J Mol Sci* **24** (2023).
- 1274 60. Tucker, E.J. *et al.* Premature Ovarian Insufficiency in CLPB Deficiency:  
1275 Transcriptomic, Proteomic and Phenotypic Insights. *J Clin Endocrinol Metab* **107**,  
1276 3328-3340 (2022).
- 1277 61. Van Bergen, N.J. *et al.* Biallelic Variants in PYROXD2 Cause a Severe Infantile  
1278 Metabolic Disorder Affecting Mitochondrial Function. *Int J Mol Sci* **23** (2022).
- 1279 62. Frazier, A.E. *et al.* Fatal perinatal mitochondrial cardiac failure caused by recurrent  
1280 de novo duplications in the ATAD3 locus. *Med (N Y)* **2**, 49-73 (2021).

- 1281 63. Borna, N.N. *et al.* Mitochondrial ribosomal protein PTCD3 mutations cause  
1282 oxidative phosphorylation defects with Leigh syndrome. *Neurogenetics* **20**, 9-25  
1283 (2019).
- 1284 64. Van Bergen, N.J. *et al.* Mutations in the exocyst component EXOC2 cause severe  
1285 defects in human brain development. *J Exp Med* **217** (2020).
- 1286 65. Lunke, S. *et al.* Integrated multi-omics for rapid rare disease diagnosis on a national  
1287 scale. *Nat Med* **29**, 1681-1691 (2023).
- 1288 66. Formosa, L.E., Dibley, M.G., Stroud, D.A. & Ryan, M.T. Building a complex complex:  
1289 Assembly of mitochondrial respiratory chain complex I. *Semin Cell Dev Biol* **76**,  
1290 154-162 (2018).
- 1291 67. Frederiksen, S.D. *et al.* Rare disorders have many faces: in silico characterization of  
1292 rare disorder spectrum. *Orphanet J Rare Dis* **17**, 76 (2022).
- 1293 68. Turner, T.N. *et al.* Proteins linked to autosomal dominant and autosomal recessive  
1294 disorders harbor characteristic rare missense mutation distribution patterns. *Hum*  
1295 *Mol Genet* **24**, 5995-6002 (2015).
- 1296 69. Dofash, L.N. *et al.* Biallelic variants in *HMGCS1* are a novel cause of  
1297 rare rigid spine syndrome. *medRxiv*, 2023.2010.2025.23297129 (2023).
- 1298 70. Gorzynski, J.E. *et al.* Ultrarapid Nanopore Genome Sequencing in a Critical Care  
1299 Setting. *N Engl J Med* **386**, 700-702 (2022).
- 1300 71. Australian Genomics Health Alliance Acute Care, F. *et al.* Feasibility of Ultra-Rapid  
1301 Exome Sequencing in Critically Ill Infants and Children With Suspected Monogenic  
1302 Conditions in the Australian Public Health Care System. *JAMA* **323**, 2503-2511  
1303 (2020).
- 1304 72. Dimmock, D. *et al.* Project Baby Bear: Rapid precision care incorporating rWGS in 5  
1305 California children's hospitals demonstrates improved clinical outcomes and  
1306 reduced costs of care. *Am J Hum Genet* **108**, 1231-1238 (2021).
- 1307 73. Guzman, U.H. *et al.* Ultra-fast label-free quantification and comprehensive  
1308 proteome coverage with narrow-window data-independent acquisition. *Nat*  
1309 *Biotechnol* (2024).
- 1310 74. Yang, Y. *et al.* Clinical whole-exome sequencing for the diagnosis of mendelian  
1311 disorders. *N Engl J Med* **369**, 1502-1511 (2013).
- 1312 75. Akesson, L.S. *et al.* Early diagnosis of Pearson syndrome in neonatal intensive care  
1313 following rapid mitochondrial genome sequencing in tandem with exome  
1314 sequencing. *Eur J Hum Genet* **27**, 1821-1826 (2019).
- 1315 76. Hoq, M. *et al.* A prospective, cross-sectional study to establish age-specific  
1316 reference intervals for neonates and children in the setting of clinical biochemistry,  
1317 immunology and haematology: the HAPPI Kids study protocol. *BMJ Open* **9**,  
1318 e025897 (2019).
- 1319 77. Robinson, D.R.L. *et al.* Applying Sodium Carbonate Extraction Mass Spectrometry  
1320 to Investigate Defects in the Mitochondrial Respiratory Chain. *Front Cell Dev Biol*  
1321 **10**, 786268 (2022).
- 1322 78. Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated  
1323 proteomic-sample processing applied to copy-number estimation in eukaryotic  
1324 cells. *Nat Methods* **11**, 319-324 (2014).

- 1325 79. Bruderer, R. *et al.* Extending the limits of quantitative proteome profiling with data-  
1326 independent acquisition and application to acetaminophen-treated three-  
1327 dimensional liver microtissues. *Mol Cell Proteomics* **14**, 1400-1410 (2015).
- 1328 80. Tyanova, S. & Cox, J. Perseus: A Bioinformatics Platform for Integrative Analysis of  
1329 Proteomics Data in Cancer Research. *Methods Mol Biol* **1711**, 133-148 (2018).
- 1330 81. Hulsén, T. arXiv:2210.04597 (2022).
- 1331 82. Yopez, V.A. *et al.* Detection of aberrant gene expression events in RNA sequencing  
1332 data. *Nat Protoc* **16**, 1276-1296 (2021).
- 1333 83. Calvo, S.E. *et al.* Molecular diagnosis of infantile mitochondrial disease with  
1334 targeted next-generation sequencing. *Sci Transl Med* **4**, 118ra110 (2012).
- 1335 84. Perez-Riverol, Y. *et al.* The PRIDE database resources in 2022: a hub for mass  
1336 spectrometry-based proteomics evidences. *Nucleic Acids Res* **50**, D543-D552  
1337 (2022).
- 1338